

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081454 A1

(51) International Patent Classification⁷: **C07D 239/36,**
A61K 31/513, A61P 3/10

Hyderabad 500016 (IN). **RAMANUJAM, Rajagopalan;**
Andhra Pradesh, Dr. Reddy's Laboratories Ltd., Discovery
Research, 7-1-27 Ameerpet, Hyderabad 500016 (IN).

(21) International Application Number: **PCT/IB02/01104**

(22) International Filing Date: **8 April 2002 (08.04.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
301/MAS/2001 9 April 2001 (09.04.2001) IN

(71) Applicant: **DR. REDDY'S LABORATORIES LTD.**
[IN/IN]; Andhra Pradesh, 7-1-27 Ameerpet, Hyderabad
500016 (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **DERIVATIVES OF ARYL ACIDS, THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHAR-
MACEUTICAL COMPOSITIONS CONTAINING THEM**




(57) Abstract: The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel b-aryl-a-oxy-substituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. (Formula I).

DERIVATIVES OF ARYL ACIDS, THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Field of the Invention

5 The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β -aryl- α -oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.



15 The present invention also relates to a process for the preparation of the above said novel compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, novel intermediates and pharmaceutical compositions containing them.

20 The compounds of this invention can be used to treat and/or prevent diabetes caused by insulin resistance or impaired glucose tolerance and to treat and prevent complications of diabetes caused by insulin resistance or impaired glucose tolerance. Complications of diabetes include but are not limited to

25 dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome,

hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis. The
5 compounds can be used as aldose reductase inhibitors or as an antiinflammatory agents.

The compounds can be used to treat and/or prevent hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in
10 which insulin resistance is the underlying pathophysiological mechanism.

The compounds can be used for the treatment and/ or prophylaxis of disorders related to Syndrome X such as hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.

15 The compounds can be used for reducing total cholesterol, body weight, blood plasma glucose, insulin, HbA_{1c}, triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma. The lowering of total cholesterol (TC), increasing high density lipoprotein (HDL) and decreasing low density lipoprotein (LDL), which have a beneficial effect on coronary heart disease and atherosclerosis.

20 The compounds of general formula (I) are useful in reducing body weight and for the treatment and/or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders. These compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, VLDL (very low density
25 lipoprotein) and LDL. The compounds of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis and nephropathy. The compounds of general formula (I) are also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance,
30 dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin

resistance, coronary heart disease and other cardiovascular disorders. These compounds may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, retinopathy, xanthoma, inflammation and for the treatment of cancer. The compounds of the present invention are useful in the treatment and/or prophylaxis of the above said diseases in combination/con-comittant with one or more HMG CoA reductase inhibitors, hypolipidemic/ hypolipoproteinemic agents such as fibric acid derivatives, fibrates, ezetimibe, orlistat, nicotinic acid, cholestyramine, colestipol and probucol.

Background Of Invention

Atherosclerosis and other peripheral vascular diseases effect the quality of life of millions of people. Therefore, considerable attention has been directed towards understanding the etiology of hypercholesterolemia and hyperlipidemia and the development of effective therapeutic strategies.

Hypercholesterolemia has been defined as plasma cholesterol level that exceeds arbitrarily defined value called "normal" level. Recently, it has been accepted that "ideal" plasma levels of cholesterol are much below the "normal" level of cholesterol in the general population and the risk of coronary artery disease (CAD) increases as cholesterol level rises above the "optimum" (or "ideal") value. There is clearly a definite cause and effect-relationship between hypercholesterolemia and CAD, particularly for individuals with multiple risk factors. Most of the cholesterol is present in the esterified forms with various lipoproteins such as low density lipoprotein (LDL), intermediate density lipoprotein (IDL), high density lipoprotein (HDL) and partially as very low density lipoprotein (VLDL). Studies clearly indicate that there is an inverse correlation between CAD and atherosclerosis with serum HDL-cholesterol concentrations. (Stampfer *et al.*, *N. Engl. J. Med.*, 325 (1991), 373-381) and the risk of CAD increases with increasing levels of LDL and VLDL.

In CAD, generally "fatty streaks" in carotid, coronary and cerebral arteries, are found which are primarily free and esterified cholesterol. Miller *et al.*, (*Br.*

Med. J., 282 (1981), 1741-1744) have shown that increase in HDL-particles may decrease the number of sites of stenosis in coronary arteries of humans, and high level of HDL-cholesterol may protect against the progression of atherosclerosis. Picardo *et al.*, (*Arteriosclerosis* 6 (1986) 434 - 441) have shown by *in vitro* experiments that HDL is capable of removing cholesterol from cells. They suggest that HDL may deplete tissues of excess free cholesterol and transfer them to the liver (Macikinnon *et al.*, *J. Biol. Chem.* 261 (1986), 2548-2552). Therefore, agents that increase HDL cholesterol would have therapeutic significance for the treatment of hypercholesterolemia and coronary heart diseases (CHD).

Obesity is a disease highly prevalent in affluent societies and in the developing world and is a major cause of morbidity and mortality. It is a state of excess body fat accumulation. The causes of obesity are unclear. It is believed to be of genetic origin or promoted by an interaction between the genotype and environment. Irrespective of the cause, the result is fat deposition due to imbalance between the energy intake versus energy expenditure. Dieting, exercise and appetite suppression have been a part of obesity treatment. There is a need for efficient therapy to fight this disease since it may lead to coronary heart disease, diabetes, stroke, hyperlipidemia, gout, osteoarthritis, reduced fertility and many other psychological and social problems.

Diabetes and insulin resistance is yet another disease which severely effects the quality of life of a large population in the world. Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations. In insulin resistance, the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes. Among the developed countries, diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyperlipidemia (*J. Clin. Invest.*, (1985) 75:809-817; *N. Engl. J. Med.* (1987) 317:350-357; *J. Clin. Endocrinol. Metab.*, (1988) 66 : 580 - 583; *J. Clin. Invest.*, (1975) 68:957-969) and other renal complications (See Patent Application No. WO 95/21608). It is now increasingly being recognized that insulin resistance and relative hyperinsulinemia have a contributory role in obesity, hypertension, atherosclerosis and type 2 diabetes

mellitus. The association of insulin resistance with obesity, hypertension and angina has been described as a syndrome having insulin resistance as the central pathogenic link-Syndrome-X.

Hyperlipidemia is the primary cause of cardiovascular (CVD) and other peripheral vascular diseases. High risk of CVD is related to the higher LDL (Low Density Lipoprotein) and VLDL (Very Low Density Lipoprotein) seen in hyperlipidemia. Patients having glucose intolerance/insulin resistance in addition to hyperlipidemia have higher risk of CVD. Numerous studies in the past have shown that lowering of plasma triglycerides and total cholesterol, in particular LDL and VLDL and increasing HDL cholesterol help in preventing cardiovascular diseases.

Peroxisome proliferator activated receptors (PPAR) are members of the nuclear receptor super family. The gamma (γ) isoform of PPAR (PPAR γ) has been implicated in regulating differentiation of adipocytes (Endocrinology, (1994) 135: 798-800) and energy homeostasis (Cell, (1995) 83: 803-812), whereas the alpha (α) isoform of PPAR (PPAR α) mediates fatty acid oxidation (Trend. Endocrin. Metab., (1993) 4: 291-296) thereby resulting in reduction of circulating free fatty acid in plasma (Current Biol. (1995) 5: 618-621). PPAR α agonists have been found useful for the treatment of obesity (WO 97/36579). It has been recently disclosed that the hypolipidaemic effect is enhanced when the molecule has both PPAR α and PPAR γ agonist activity and suggested to be useful for the treatment of syndrome X (WO 97/25042). Synergism between the insulin sensitizer (PPAR γ agonist) and HMG CoA reductase inhibitor has been observed which may be useful for the treatment of atherosclerosis and xanthoma. (EP 0 753 298).


It is known that PPAR γ plays an important role in adipocyte differentiation (Cell, (1996) 87, 377-389). Ligand activation of PPAR is sufficient to cause complete terminal differentiation (Cell, (1994) 79, 1147-1156) including cell cycle withdrawal. PPAR γ is consistently expressed in certain cells and activation of this nuclear receptor with PPAR γ agonists would stimulate the terminal differentiation of adipocyte precursors and cause morphological and molecular changes characteristics of a more differentiated, less malignant state (Molecular Cell, (1998), 465-470; Carcinogenesis, (1998), 1949-53; Proc. Natl. Acad. Sci., (1997) 94, 237-241) and

inhibition of expression of prostate cancer tissue (Cancer Research (1998), 58:3344-3352). This would be useful in the treatment of certain types of cancer, which express PPAR γ and could lead to a quite nontoxic chemotherapy.

Leptin resistance is a condition wherein the target cells are unable to respond to leptin signals. This may give rise to obesity due to excess food intake and reduced energy expenditure and cause impaired glucose tolerance, type 2 diabetes, cardiovascular diseases and such other interrelated complications. Kallen *et al* (Proc. Natl. Acad. Sci., (1996) 93, 5793-5796) have reported that insulin sensitizers which perhaps due to their PPAR agonist expression and lower plasma leptin concentrations. However, it has been recently disclosed that compounds having insulin sensitizing property also possess leptin sensitization activity. They lower the circulating plasma leptin concentrations by improving the target cell response to leptin (WO 98/02159).


A few aryloxy alkanoic acids, their derivatives, and their analogs have been reported to be useful in the treatment of hyperglycemia and hypercholesterolemia. Some of such compounds described in the prior art are outlined below:

i) International publication No. WO 00/49005 disclose the compounds of general formula (II a)



wherein Het is an optionally substituted, saturated partially saturated or fully unsaturated 8 to 10 membered bicyclic ring, R¹ is optionally substituted aryl or optionally substituted heteroaryl, R² is hydrogen halogen, lower alkyl or lower alkoxy, L¹ is an -R³-R⁴=linkage where R³ is alkylene, alkenylene or alkynylene and R⁴ is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryliidyl, -C(=Z²)-NR⁵, NR⁵-C(=Z²), -Z²-, -C(=O)-, -C(=NOR⁵)-, -NR⁵-, NR⁵-C(=Z²)-NR⁵, SO₂-NR⁵ NR⁵-SO₂, -O-C(=O)-, -C(=O)-O-, -O-C(=O)-NR⁵, -NR⁵-C(=O)-O-; L² is optionally substituted alkylene or alkenylene, Y is carboxy or an acid bioisostere and Z¹ is NR⁵ and the corresponding N-oxides and their prodrugs and pharmaceutically acceptable salts and solvates.


An example of these compounds is shown in formula (II b)



ii) International publication No. WO 98/31359 disclose the compounds of general formula (IIc)




- 5 wherein X represents NH_2 , $NH-C(=NH)-$, and the like or 5 or 6 membered monocyclic aromatic or nonaromatic ring system containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S wherein the mono or bicyclic ring system either substituted or unsubstituted, or a 9 to 14 membered polycyclic ring system, wherein
- 10 one or more of the rings is aromatic and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S, wherein the polycyclic ring system either substituted or unsubstituted; Y is selected from C_{0-8} alkylene, C_{0-8} cycloalkyl, C_{0-8} alkylene- NR^{10} -CO- C_{0-8} alkylene, C_{0-8} alkylene-CONR¹⁰- C_{0-8} alkylene, C_{0-8} alkylene-O- C_{0-8} alkylene, C_{0-8} alkylene- NR^{10} - C_{0-8} alkylene, C_{0-8} alkylene-S(O)₀₋₂- C_{0-8} alkylene, C_{0-8} alkylene-S(O)₀₋₂-NR¹⁰- C_{0-8} alkylene, C_{0-8} alkylene-NR¹⁰-S(O)₀₋₂- C_{0-8} alkylene, C_{0-8} alkylene-CO- C_{0-8} alkylene, $(CH_2)_{0-6}$ -aryl $(CH_2)_{0-6}$, $(CH_2)_{0-6}$ -aryl-CO- $(CH_2)_{0-6}$, $(CH_2)_{0-6}$ -aryl-CO-NR¹⁰- $(CH_2)_{0-6}$, $(CH_2)_{0-6}$ -arylNR¹⁰CO $(CH_2)_{0-6}$, or $(CH_2)_{0-8}$ -CH(OR¹)(CH_2)₀₋₈; Z and A are each independently selected from $(CH_2)_m$, $(CH_2)_mO(CH_2)_n$, $(CH_2)_mNR^{11}(CH_2)_n$, $(CH_2)_mNR^{11}CONR^{12}(CH_2)_n$, $(CH_2)_mCONR^{11}(CH_2)_n$, $(CH_2)_mCO(CH_2)_n$, $(CH_2)_mCS(CH_2)_n$, $(CH_2)_mNR^{11}SO_2(CH_2)_n$, $(CH_2)_mSNR^{11}(CH_2)_n$, $(CH_2)_mSO_2NR^{11}(CH_2)_n$, $(CH_2)_mNR^{11}SO_2(CH_2)_n$, $(CH_2)_mCR^{11}=CR^{12}(CH_2)_n$, $(CH_2)_mC\equiv C(CH_2)_n$; where m and n are each independently an integer from 0 to 6; Aryl is a 6 membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms and either
- 25 unsubstituted or substituted with R⁸ and R⁹; B is




where p is an integer from 1 to 3, R⁶ is selected from hydrogen, fluorine, (C₁₋₈) alkyl, hydroxy, hydroxy (C₁₋₆) alkyl, carboxy (C₀₋₆)alkyl, (C₁₋₆) alkyloxy, (C₁₋₆)alkylcarbonyl, aryl (C₁₋₈) alkylcarbonyl, (C₁₋₆)alkylcarbonyloxy, aryl (C₀₋₆) alkylcarbonyloxy, (C₁₋₆) alkylaminocarbonyloxy, (C₃₋₈)cycloalkyl, aryl (C₀₋₆) alkyl, (C₀₋₆) alkylamino (C₀₋₆) alkyl, (C₀₋₆) dialkylamino (C₀₋₆) alkyl, (C₀₋₆) dialkylamino (C₀₋₆) alkyl, (C₁₋₈) alkylsulfonylamino (C₀₋₆) alkyl, aryl (C₀₋₆) alkylsulfonylamino (C₀₋₆) alkyl, (C₁₋₈) alkoxycarbonylamino (C₀₋₈) alkyl, aryl (C₀₋₈) alkylalkoxycarbonylamino (C₀₋₈) alkyl, (C₁₋₈) alkylcarbonylamino (C₀₋₆) alkyl, aryl (C₀₋₆) alkylcarbonylamino (C₀₋₆) alkyl and the like; R⁷ is selected from (C₇₋₂₀) polycyclyl (C₁₋₈) alkylsulfonylamino (C₀₋₈) alkyl and the like, R¹³ is selected from hydroxy, (C₁₋₈) alkyloxy and the like;

An example of these compounds is shown in formula (IId)




15 iii) International publication No. WO 94/12181 disclose the compounds of general formula (IIe)



aryl is a 6 membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms and either unsubstituted or substituted with R⁸ and R⁹; X represents NH₂, NH-C(=NH)-, and the like or 4 to 10 membered mono or polycyclic aromatic or nonaromatic ring system and containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S either unsubstituted or substituted; Y is selected from C₀₋₈ alkyl, C₄₋₁₀ cycloalkyl, C₀₋₈ alkyl-NR³-CO-C₀₋₈ alkyl, C₀₋₈alkyl-CONR³-C₀₋₈ alkyl, C₀₋₈ alkyl-O-C₀₋₈ alkyl, C₀₋₈ alkyl-S(O)_n-C₀₋₈ alkyl, (CH₂)₀₋₈ aryl-(CH₂)₀₋₈, (CH₂)₀₋₆ aryl-SO_n-, (CH₂)₀₋₈ aryl-CO-(CH₂)₀₋₈, (CH₂)₀₋₆ aryl-SO₂-(CH₂)₀₋₆-, (CH₂)₀₋₆ NR³-(CH₂)₀₋₆-, (CH₂)₀₋₆ aryl-CH(OH)-(CH₂)₀₋

6-, $(\text{CH}_2)_{0-8}-\text{CONH}-(\text{CH}_2)_{0-8}-$, C_{0-8} alkyl- $\text{SO}_2-\text{NR}^3-\text{C}_{0-8}$ alkyl, C_{0-8} alkyl- $\text{CO}-\text{C}_{0-8}$ alkyl, C_{0-8} alkyl- $\text{CH}(\text{OH})-\text{C}_{0-8}$ alkyl, where n is an integer from 0-2; Z and A are independently chosen from $(\text{CH}_2)_m$, $(\text{CH}_2)_m\text{O}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{NR}^3(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{NR}^3(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{CONR}^{11}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{CO}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{CS}(\text{CH}_2)_n$,
 5 $(\text{CH}_2)_m\text{SO}_2(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{S}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{SO}_2(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{SO}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{SO}_2\text{NR}^3(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{NR}^3\text{SO}_2(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{CR}^3=\text{CR}^4(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{C}\equiv\text{C}(\text{CH}_2)_n$, $(\text{CH}_2)_m\text{CH}(\text{OH})(\text{CH}_2)_n$; where m and n are each independently an integer from 0 to 6; Aryl is a 6 membered aromatic ring system containing 0, 1, 2, 3 or 4 N atoms and either unsubstituted or substituted with R^5 , provided that when A is
 10 $(\text{CH}_2)_m$, the Aryl ring, bonded by Z and A must contain at least one heteroatom;


B is




R^6 , R^7 , R^8 , R^9 , R^{10} and R^{11} , are independently selected from hydrogen, fluorine, (C_{1-8}) alkyl, hydroxy, hydroxy (C_{1-6}) alkyl, carboxy (C_{0-6}) alkyl, (C_{1-6}) alkyloxy, aryl (C_{0-6}) alkyloxy, (C_{3-8}) cycloalkyl, aryl (C_{0-6}) alkyl, (C_{1-6}) alkylcarbonyloxy, (C_{0-6}) alkylamino (C_{0-6}) alkyl and the like;

R^{12} is selected from hydroxy, (C_{1-8}) alkyloxy, aryl (C_{0-6}) alkyl and the like;


An example of these compounds is shown in formula (IIf)



20 iv) International publication No. WO 93/16697 and U.S. Patent No. 5,227,490 disclose the compounds of general formula (IIg)



wherein R^1 is chosen independently from (C_1-C_6) alkyl, aryl (C_4-C_{10}) alkyl, aryl, carboxy, (C_1-C_6) alkyloxy, carboxy (C_0-C_6) alkyl, hydroxy (C_0-C_6) alkyl, (C_1-C_4) alkylsulfonyl (C_0-C_6) alkyl, (C_0-C_4) alkylamino (C_0-C_6) alkyl, aryl (C_0-C_{10}) alkylamino (C_0-C_6) alkyl, (C_2-C_{10}) acylamino (C_0-C_6) alkyl, (C_1-C_4) carboalkoxy (C_0-C_6) alkyl or halogen atom; R^2 is chosen from hydrogen, halogen, hydroxy, (C_1-C_6) alkyloxy, aryl (C_0-C_4) alkyl, aryl (C_0-C_6) alkyloxy, (C_1-C_6) alkyl wherein the alkyl group is unsubstituted or substituted with one or more groups chosen from hydroxy, (C_1-C_4) alkyloxy, amino (C_1-C_{10}) alkylcarbonyl, aryl (C_0-C_{10}) alkylcarbonyl, aryl (C_0-C_{10}) alkylcabonylamino, (C_1-C_6) alkylsulfonyl, aryl (C_0-C_6) alkylsulfonyl, (C_1-C_6) alkylsulfonylamino, aryl (C_0-C_{10}) alkylsulfonylamino, (C_1-C_{10}) alkyloxycarbonylamino, aryl (C_0-C_6) alkylamino, aryl (C_0-C_6) alkylcarbonylamino, amino, carboxy, aryl, carbonyl-P-or SO_2 -P wherein P is a single L or D amino acid or a sequence of 2-4 L or D amino acids connected by amide linkage; or R^2 represents carboxyl, (C_1-C_6) alkylcarbonyl, aryl (C_1-C_{10}) alkylcarbonyl, (C_1-C_6) alkyloxycarbonylamino (C_1-C_6) alkyl, (C_1-C_6) alkylaminocarbonylamino (C_1-C_6) alkyl, aryl (C_0-C_6) alkylaminocarbonylamino (C_1-C_6) alkyl, aryl (C_0-C_6) alkyloxycarbonylamino (C_1-C_6) alkyl, (C_1-C_6) alkoxycarbonyl or aryl (C_0-C_6) alkyloxycarbonyl and provided that when there is more than one R^2 on the same carbon atom they may be the same or different; R^3 is hydrogen, (C_1-C_6) alkyl, aryl (C_1-C_{10}) alkyl; Z is NR^4R^5 wherein R^4 and R^5 are independently hydrogen, (C_1-C_6) alkyl, aryl (C_1-C_{10}) alkyl wherein said alkyl groups are unsubstituted or substituted with (C_1-C_4) alkyloxy, carboxy (C_0-C_6) alkyl, hydroxy, halogen or Z represents a 4-9 membered mono or bicyclic ring system containing 1, 2 or 3 heteroatoms chosen from N, O or S and either unsubstituted or substituted with R^4 or R^5 or




Y is (C_1-C_{10}) alkyl either unsubstituted or unsubstituted with one or more groups selected from R^4 or R^5 ; or Y represents (C_4-C_8) cycloalkyl, aryl, (C_0-C_3) alkylaryl (C_0-C_3) alkyl, (C_0-C_3) alkylaryl (C_0-C_3) alkylcarbonyl, (C_0-C_3) alkylaryl (C_0-C_3) alkylcarboxamido, (C_0-C_3) alkylaryloxy (C_0-C_3) alkyl, (C_0-C_3) alkyloxy (C_0-C_6) alkyl,




or $-(\text{CH}_2)_m\text{-Q-(CH)}_n$ where Q is a $\text{C}_2\text{-C}_8$ membered heterocyclic ring containing 1, 2 or 3 heteroatoms chosen from N, O or S and substituted or unsubstituted with oxo, thio, or $(\text{C}_1\text{-C}_6)$ alkyl and m and n are chosen from the integers 0, 1, 2 or 3;

- 5 X is O, S, SO, SO_2 , CO, $-\text{NR}^4\text{CO-}$, $\text{CONR}^4\text{-}$, $-\text{CH}_2\text{-}$, $-\text{CH=CH-}$, $-\text{C=C-}$, $-\text{NR}^4\text{CS-}$, $-\text{CSNR}^4\text{-}$ or $\text{SO}_2\text{NR}^4\text{-}$ or $\text{NR}^4\text{SO}_2\text{-}$; An example of these compounds is shown in formula (IIh)




- v) International publication No. WO 00/05223 disclose the compounds of general formula (IIi)




- where A is a bicyclic heteroaryl, optionally substituted with one or more substituents; B is linker group connecting group A to groups D and comprising a 3 or 4 atom linker where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and is optionally substituted with one or more C_{1-6} alkyl groups or two of such adjacent alkyl substituents may form a ring; C is aryl or mono or bicyclic heteroaryl, each or which can be optionally substituted; D is an aryl or heteroaryl, both or which are optionally substituted, R^1 is hydrogen, C_{1-5} alkyl, C_{1-3} alkanoyl, or C_{1-3} alkoxy carbonyl, R^2 to R^5 are each independently selected from hydrogen, C_{1-6} alkyl, aryl and heteroaryl containing up to 2 heteroatoms chosen from oxygen, sulphur and nitrogen, the aryl and heteroaryl optionally substituted with C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-6} alkylamino, C_{1-4} alkyl C_{1-6} alkyloxy, C_{1-6} alkylamino C_{1-6} alkyl, nitro, cyano, halogen, trifluoromethyl, hydroxy, $(\text{CH}_2)_p\text{OH}$ where p is 1 or 2, $-\text{COR}^a$ and $-\text{CONR}^a\text{R}^b$, where R^a and R^b are
- 25 independently selected from hydrogen and C_{1-6} alkyl or two of R^2 to R^5 can be taken

together to form a 3 to 7 membered ring, R^6 is an acidic functional group, r and s are each independently 0 or with the proviso that r and s cannot both be 0.

An example of these compounds is shown in formula (IIj)




5 vi) International publication No. WO 00/64888 disclose the compounds
of general formula (IIIk)



Ar^1 and Ar^2 are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclenyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylcyclenyl or fused heteroarylheterocyclyl; A is O, S, SO, OS₂, NR¹³, C(O), NR¹⁴C(O), C(O)NR¹⁴, NR¹⁴C(O)N(R¹⁵), C(R¹⁴)=N; chemical bond and the like; B is O, S, NR¹⁹, a chemical bond, C(O), N(R²⁰)C(O) or C(O)N(R²⁰); E is a chemical bond or an ethylene groups; a is 0-6; b is 0-4; c is 0-4; d is 0-6; g is 1-5; h is 1-4; R¹, R³, R⁵ and R⁷ are independently hydrogen, halogen alkyl, carbonyl, alkoxy-carbonyl, or aralkyl; R², R⁴, R⁶ and R⁸ are independently -(CH₂)_q-X; q is 0-3; X is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carbonyl, alkoxy-carbonyl, tetrazolyl, acyl, acylHNSO₂, and the like; Z is R²¹O₂C, R²¹OC, cyclo-imide; CN, R²¹O₂SHNCO, R²¹O₂SNH, R²¹NCO, R²¹O-2,4-thiazolidinonyl or tetrazolyl.

An example of these compounds is shown in formula (III)



Summary of the Invention

The present invention provides novel compounds of the formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having good stability and solubility, which can be used for the treatment and / or prophylaxis of diseases related to increased levels of lipids, especially to treat hyperlipidemia, and for the treatment of type II diabetes, impaired glucose intolerance, leptin resistance, atherosclerosis, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, coronary artery disease and other cardiovascular disorders, renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, eating disorders, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, retinopathy, arteriosclerosis, xanthoma or cancer with better efficacy, potency and lower toxicity.

The present invention provides novel compounds of the formula (I) and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures which may have agonist activity against PPAR α and / or PPAR γ , and optionally inhibit HMG CoA reductase, in addition to agonist activity against PPAR α and / or PPAR γ .

The present invention provides novel compounds of the formula (I) and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activities, without toxic effect or with reduced toxic effect.


The present invention provides a process for the preparation of novel compounds of the formula (I) as defined above, their analogs, their tautomeric forms,

their stereoisomers, their pharmaceutically acceptable salts, their polymorphs and their pharmaceutically acceptable solvates.

The present invention provides pharmaceutical compositions containing novel compounds of the general formula (I), their analogs, their derivatives, their tautomers, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, solvates or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.

Detailed Description Of The Invention

The present invention relates to compounds having the general formula (I)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures wherein X represents O or S; the groups R¹, R² and the group R³ when attached to the carbon atom, may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxy carbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxy carbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R³ when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy, alkoxycarbonyl, aryloxy carbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl groups, carboxylic acid or its derivatives, or sulfonic

acid or its derivatives; the linking group represented by $-(CH_2)_m-W-(CH_2)_n-$ is attached either through nitrogen atom or through carbon atom; W represents O, S, NR^7 , $-C(=O)$, $-O-C(=O)$, $C(=O)-O$, $C(=O)-NR^7$, $-O-C(=O)-NR^7$, $NR^7-(CH_2)_nC(=O)-NR^7$, $NR^7-C(=O)-O-$, $NR^7-C(=O)-NR^7$, $NR^7-C(=O)$, SO_2-NR^7 , NR^7-SO_2 , where R^7 represents hydrogen, (C_1-C_{12}) alkyl, or substituted or unsubstituted aryl, aralkyl group; m and n are integers ranging from 0-4; Ar represents substituted or unsubstituted divalent single or fused aromatic or heterocyclic group; R^4 and R^5 may be same or different and represent hydrogen, hydroxy, alkoxy, halogen or substituted or unsubstituted groups selected from (C_1-C_{12}) alkyl, aralkyl or heteroaralkyl groups; R^6 may be hydrogen or substituted or unsubstituted groups selected from (C_1-C_{12}) alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents oxygen or NR^8 , where R^8 represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; R^6 and R^8 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, one or two nitrogen atoms and may optionally contain one or more heteroatoms selected from oxygen, or sulfur; Q represents O, S, SO, SO_2 or NR^9 wherein R^9 represents hydrogen, substituted or unsubstituted groups selected from (C_1-C_{12}) alkyl, cycloalkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; p is an integer of 0 or 1;

Suitable groups represented by R^1 , R^2 and the group R^3 when attached to carbon atom, may be selected from hydrogen, halogen atom such as fluorine, chlorine, bromine or iodine; hydroxy, cyano, nitro, formyl, substituted or unsubstituted (C_1-C_{12}) alkyl group, especially, linear or branched (C_1-C_{10}) alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like; cyclo (C_3-C_6) alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; (C_1-C_6) alkoxy such as methoxy, ethoxy, propyloxy, butyloxy, iso-propyloxy and the like, which may be substituted; cyclo (C_3-C_6) alkoxy group such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, the cycloalkoxy group may be substituted; aryl group such as phenyl, naphthyl and

the like, the aryl group may be substituted; aryloxy group such as phenoxy, naphthyloxy and the like, the aryloxy group may be substituted; aralkyl such as benzyl, phenethyl, $C_6H_5CH_2CH_2CH_2$, naphthylmethyl and the like, the aralkyl group may be substituted and the substituted aralkyl is a group such as $CH_3C_6H_4CH_2$, Hal-
5 $C_6H_4CH_2$, $CH_3OC_6H_4CH_2$, $CH_3OC_6H_4CH_2CH_2$ and the like; aralkoxy group such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy and the like, the aralkoxy group may be substituted; heterocyclyl groups such as aziridinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl and the like, the heterocyclyl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl, pyrrolyl,
10 oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuryl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, pyridinemethyl, furanethyl, pyridineethyl, oxazole-methyl, oxazolethyl and the like, the heteroaralkyl group may be substituted; heteroaryloxy and heteroaralkoxy, wherein heteroaryl and heteroaralkyl moieties are as defined earlier
15 and may be substituted; acyl group such as acetyl, propionyl, benzoyl and the like, the acyl group may be substituted; acyloxy group such as $OOCCMe$, $OOCCEt$, $OOCCPh$ and the like, which may be substituted; acylamino groups such as $NHCOCH_3$, $NHCOC_2H_5$, $NHCOC_3H_7$, $NHCOC_6H_5$ and the like, which may be substituted; monoalkylamino group such as $NHCH_3$, NHC_2H_5 , NHC_3H_7 , NHC_6H_{13} , and the like,
20 which may be substituted; dialkylamino group such as $N(CH_3)_2$, $NCH_3(C_2H_5)$, $N(C_2H_5)_2$ and the like, which may be substituted; arylamino group such as HNC_6H_5 , $NCH_3(C_6H_5)$, $NHC_6H_4CH_3$, NHC_6H_4-Hal and the like, which may be substituted; aralkylamino group such as $C_6H_5CH_2NH$, $C_6H_5CH_2CH_2NH$, $C_6H_5CH_2NCH_3$ and the like, which may be substituted; amino group; amino(C_1-C_6) alkyl such as
25 aminomethyl, aminoethyl, aminopropyl and the like, which may be substituted; (C_1-C_6)hydroxyalkyl, which may be substituted; alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like, the alkoxyalkyl group may be substituted; aryloxyalkyl group such as $C_6H_5OCH_2$, $C_6H_5OCH_2CH_2$, naphthyloxymethyl and the like, which may be substituted;
30 aralkoxyalkyl group such as $C_6H_5CH_2OCH_2$, $C_6H_5CH_2OCH_2CH_2$ and the like, which may be substituted; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl and the like, which may be substituted; aryloxycarbonyl group such as phenoxycarbonyl,

naphthyloxycarbonyl and the like, the aryloxycarbonyl group may be substituted; aralkoxycarbonyl group such as benzyloxycarbonyl, phenethyloxycarbonyl, naphthylmethoxycarbonyl and the like, which may be substituted; thio(C_1-C_6)alkyl, which may be substituted; (C_1-C_6)alkylthio which may be substituted; 5 alkoxy-carbonylamino group such as $NHCOOC_2H_5$, $NHCOOCH_3$ and the like, which may be substituted; aryloxycarbonylamino group such as $NHCOOC_6H_5$, $NCH_3COOC_6H_5$, $NC_2H_5COOC_6H_5$, $NHCOOC_6H_4CH_3$, $NHCOOC_6H_4OCH_3$ and the like, which may be substituted; aralkoxycarbonylamino group such as $NHCOOCH_2C_6H_5$, $NHCOOCH_2CH_2C_6H_5$, $N(CH_3)COOCH_2C_6H_5$, 10 $N(C_2H_5)COOCH_2C_6H_5$, $NHCOOCH_2C_6H_4CH_3$, $NHCOOCH_2C_6H_4OCH_3$ and the like, which may be substituted; carboxylic acid or its derivatives such as amides, like $CONH_2$, $CONHMe$, $CONMe_2$, $CONHEt$, $CONEt_2$, $CONHPh$ and the like, the carboxylic acid derivatives may be substituted; sulfonic acid or its derivatives such as amides like SO_2NH_2 , SO_2NHMe , SO_2NMe_2 , SO_2NHCF_3 and the like, the sulfonic 15 acid derivatives may be substituted.

When the groups represented by R^1 , R^2 and the group R^3 when attached to carbon atom are substituted, the substituents may be selected from halogen, hydroxy, nitro, thio or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, alkoxyalkyl, aryloxyalkyl, 20 aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, alkoxy-carbonyl, monoalkylamino, dialkylamino, alkylthio, carboxylic acid or its derivatives or sulfonic acid or its derivatives. These groups are as defined above.

It is preferred that the substituents on by R^1 , R^2 and the group R^3 represents 25 halogen atom such as fluorine, chlorine or bromine; alkyl group such as methyl, ethyl, iso-propyl, n-propyl, n-butyl; cycloalkyl group such as cyclopropyl; aryl group such as phenyl; aralkyl group such as benzyl; (C_1-C_3)alkoxy, benzyloxy, hydroxy group, acyl or acyloxy groups.

Suitable groups represented by R^3 when attached to nitrogen atom may be 30 selected from hydrogen, hydroxy, formyl; substituted or unsubstituted (C_1-C_{12})alkyl group, especially, linear or branched (C_1-C_6)alkyl group, such as methyl, ethyl, n-

propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, hexyl and the like; (C₁-C₆)alkoxy such as methoxy, ethoxy, propyloxy, butyloxy, iso-propyloxy and the like, which may be substituted; cyclo(C₃-C₆)alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; cyclo(C₃-C₆)alkoxy group such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, the cycloalkoxy group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl such as benzyl, phenethyl, C₆H₅CH₂CH₂CH₂, naphthylmethyl and the like, the aralkyl group may be substituted and the substituted aralkyl is a group such as CH₃C₆H₄CH₂, Hal-C₆H₄CH₂, CH₃OC₆H₄CH₂, CH₃OC₆H₄CH₂CH₂ and the like; aryloxy group such as phenoxy, naphthyloxy and the like, the aryloxy group may be substituted; aralkoxy group such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy and the like, the aralkoxy group may be substituted; heterocyclyl groups such as aziridiny, pyrrolidiny, morpholiny, piperidiny, piperaziny and the like, the heterocyclyl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuryl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, pyridinemethyl, furanethyl, pyridineethyl, oxazolemethyl, oxazolethyl and the like, the heteroaralkyl group may be substituted; heteroaryloxy and heteroaralkoxy, wherein heteroaryl and heteroaralkyl moieties are as defined earlier and may be substituted; monoalkylamino group such as NHCH₃, NHC₂H₅, NHC₃H₇, NHC₆H₁₃ and the like, which may be substituted; dialkylamino group such as N(CH₃)₂, NCH₃(C₂H₅), N(C₂H₅)₂ and the like, which may be substituted; acylamino groups such as NHCOCH₃, NHCOC₂H₅, NHCOC₃H₇, NHCOC₆H₅ and the like, which may be substituted; arylamino group such as HNC₆H₅, NCH₃(C₆H₅), NHC₆H₄CH₃, NHC₆H₄-Hal and the like, which may be substituted; amino group; aralkylamino group such as C₆H₅CH₂NH, C₆H₅CH₂CH₂NH, C₆H₅CH₂NCH₃ and the like, which may be substituted; amino(C₁-C₆)alkyl such as aminomethyl, aminoethyl, aminopropyl and the like, which may be substituted; (C₁-C₆)hydroxyalkyl, which may be substituted; alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like, the alkoxyalkyl group may be substituted;

aryloxyalkyl group such as $C_6H_5OCH_2$, $C_6H_5OCH_2CH_2$, naphthyloxymethyl and the like, which may be substituted; aralkoxyalkyl group such as $C_6H_5CH_2OCH_2$, $C_6H_5CH_2OCH_2CH_2$ and the like, which may be substituted; alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl and the like, which may be substituted;

5 aryloxycarbonyl group such as phenoxycarbonyl, naphthyloxycarbonyl and the like, which may be substituted; aralkoxycarbonyl group such as benzyloxycarbonyl, phenethyloxycarbonyl, naphthylmethoxycarbonyl and the like, which may be substituted; carboxylic acid or its derivatives such as amides, like $CONH_2$, $CONHMe$, $CONMe_2$, $CONHEt$, $CONEt_2$, $CONHPh$ and the like, the carboxylic acid

10 derivatives may be substituted; sulfonic acid derivatives such as amides, like SO_2NH_2 , SO_2NHMe , SO_2NMe_2 , SO_2NHCF_3 and the like, the sulfonic acid derivatives may be substituted.

When the groups represented by R^3 attached to nitrogen are substituted, substituents may be selected from halogen such as fluorine or chlorine; hydroxy,

15 acyl, acyloxy or amino groups. These groups are as defined above.

Suitable groups represented by R^4 and R^5 may be selected from hydrogen, hydroxy, (C_1-C_3) alkoxy group such as methoxy, ethoxy, propoxy and the like; halogen atom such as fluorine, chlorine, bromine or iodine; (C_1-C_{12}) alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl, and the like,

20 which may be substituted; aralkyl such as benzyl, phenethyl and the like, which may be substituted or heteroaralkyl such as pyridinemethyl, pyridineethyl, furanmethyl, oxazolemethyl, oxazolethyl, furanethyl and the like, the heteroaralkyl group may be substituted. The substituents are selected from halogen, hydroxy or (C_1-C_6) alkyl groups.

Suitable groups represented by R^6 may be selected from hydrogen, linear or branched (C_1-C_{16}) alkyl, preferably (C_1-C_{12}) alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, pentyl, hexyl, octyl and the like, the alkyl group may be substituted; (C_3-C_7) cycloalkyl such as cyclopropyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; heteroaryl group

30 such as pyridyl, thienyl, pyrrolyl, furyl and the like, the heteroaryl group may be

substituted; heteroaralkyl group such as furanmethyl, furanethyl, pyridinemethyl, pyridineethyl, oxazolemethyl, oxazoleethyl and the like, the heteroaralkyl group may be substituted; aralkyl group such as benzyl, phenethyl and the like, the aralkyl group may be substituted; heterocyclyl group such as aziridinyl, pyrrolidinyl, piperidinyl and the like, the heterocyclyl group may be substituted. The substituents on R^6 may be selected from halogen, hydroxy, nitro or unsubstituted or substituted groups selected from (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, (C_1-C_6) alkoxy, (C_3-C_7) cycloalkoxy, aryl, aralkyl, aralkoxy (C_1-C_6) alkyl, heterocyclyl, heteroaryl, heteroaralkyl, (C_1-C_6) acyl, (C_1-C_6) acyloxy, hydroxy (C_1-C_6) alkyl, amino, (C_1-C_6) acylamino, arylamino, amino (C_1-C_6) alkyl, aryloxy, aralkoxy, (C_1-C_6) alkoxycarbonyl, (C_1-C_6) alkylamino, (C_1-C_6) alkoxyalkyl, (C_1-C_6) alkylthio, thio (C_1-C_6) alkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives. The substituents are as defined above.

Suitable groups represented by R^7 may be selected from hydrogen, linear or branched (C_1-C_{12}) alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl, nonyl and the like; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl such as benzyl, phenethyl, $C_6H_5CH_2CH_2CH_2$, naphthylmethyl and the like, the aralkyl group may be substituted. The substituents may be selected from hydroxy, halogen, linear or branched (C_1-C_{10}) alkyl such as methyl, ethyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like; (C_1-C_6) alkoxy such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy and the like; aryl group such as phenyl, naphthyl and the like; aralkyl group such as benzyl, phenethyl, naphthylmethyl and the like.

Suitable groups represented by R^8 may be selected from hydrogen, linear or branched (C_1-C_{16}) alkyl, preferably (C_1-C_{12}) alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, pentyl, hexyl, octyl and the like, the alkyl group may be substituted; hydroxy (C_1-C_6) alkyl, the hydroxy (C_1-C_6) alkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl group such as benzyl, phenethyl and the like, the aralkyl group may be substituted; heterocyclyl group such as aziridinyl, pyrrolidinyl,

piperidinyl and the like, the heterocyclyl group may be substituted; heteroaryl group such as pyridyl, thienyl, pyrrolyl, furyl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, furanethyl, pyridinemethyl, pyridineethyl, oxazole-methyl, oxazolethyl and the like, the heteroaralkyl group may be substituted. The substituents may be selected from hydroxy, halogen, linear or branched (C₁-C₁₀)alkyl such as methyl, ethyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like; (C₁-C₆)alkoxy such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy and the like; aryl group such as phenyl, naphthyl and the like; aralkyl group such as benzyl, phenethyl, naphthylmethyl and the like.

Suitable ring structures formed by R⁶ and R⁸ together may be selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and the like.

Suitable groups represented by R⁹ may be selected from hydrogen, substituted or unsubstituted (C₁-C₁₂)alkyl group, especially, linear or branched (C₁-C₁₀)alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl, nonyl and the like; cyclo(C₃-C₆)alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl such as benzyl, phenethyl, C₆H₅CH₂CH₂CH₂, naphthylmethyl and the like, the aralkyl group may be substituted; heterocyclyl groups such as aziridinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl and the like, the heterocyclyl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, tetrazolyl, benzopyranyl, benzofuryl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, furanethyl, pyridinemethyl, pyridineethyl, oxazole-methyl, oxazolethyl and the like, the heteroaralkyl group may be substituted; hydroxy(C₁-C₆)alkyl, which may be substituted. The substituents may be selected from hydroxy, halogen, (C₁-C₆)alkyl or (C₁-C₆)alkoxy groups.

Suitable groups represented by Ar may be selected from substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl,

indolyl, indolynyl, azaindolyl, azaindolynyl, pyrazolyl, benzothiazolyl, benzoxazolyl and the like. The substituents on the group represented by Ar may be selected from linear or branched optionally halogenated (C₁-C₆)alkyl, optionally halogenated (C₁-C₃)alkoxy, halogen, nitro, acyl, amino, acylamino, thio or carboxylic or sulfonic acids and their derivatives. The substituents are defined as they are for R¹-R⁴.

It is more preferred that Ar represent substituted or unsubstituted divalent, phenylene, naphthylene, benzofuryl, indolyl, indolynyl, quinolynyl, azaindolyl, azaindolynyl, benzothiazolyl or benzoxazolyl groups.

It is still more preferred that Ar is represented by divalent phenylene, naphthylene or benzofuryl, which may be unsubstituted or substituted by alkyl, haloalkyl, methoxy or haloalkoxy groups.

Suitable n is an integer ranging from 0 to 4, preferably n represents an integer 0 to 2.

Suitable m is an integer ranging from 1 to 2.

Suitable p is an integer ranging of 0 or 1.

Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine, and the like; chiral bases like alkylphenylamine, glycinol, phenyl glycinol and the like, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids such as D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,

alkynyl; ammonium or substituted ammonium salts and aluminum salts. Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.

Particularly useful compounds according to the present invention include:

- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl (heptyl) carbamoyl]phenoxy}-2-methyl propanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl) ethyl carbamoyl]phenoxy}-2-methyl propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl) ethyl carbamoyl]phenoxy}-2-methyl propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl) ethyl carbamoyl]phenoxy}-2-methyl propanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl carboxamido]phenoxy}-2-methyl propanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl carboxamido]phenoxy}-2-methyl propanoate;

- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl carboxamido)phenoxy]-2-methyl propanoate;
- (±) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- 5 (+) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- (-) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- 10 (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- 15 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- 20 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate;
- 25 (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl carboxamido)phenoxy]octanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl carboxamido)phenoxy]octanoate;
- 30

- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]octanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoate;
- 5 (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoate;
- (±) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
- 10 (+) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
- (-) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
- 15 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy}pentanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy}pentanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy}pentanoate;
- 20 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoate;
- 25 (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoate;
- 30

- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoate;
- 5 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}pentanoate;
- 10 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}pentanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}pentanoate;
- 15 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino]phenylsulfanyl}-3-methyl butanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino]phenylsulfanyl}-3-methyl butanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino]phenylsulfanyl}-3-methyl butanoate;
- 20 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} butanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} butanoate;
- 25 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl}-3-methyl butanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl}-3-methyl butanoate;
- 30

- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl}-3-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}-4-methyl pentanoate;
- 5 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}-4-methyl pentanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}-4-methyl pentanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl]phenoxy}acetate;
- 10 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl]phenoxy}acetate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl]phenoxy}acetate;
- 15 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoate;
- 20 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoate;
- 25 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}pentanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}pentanoate;
- 30

- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino}pentanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] (heptyl) anilino}propanoate;
- 5 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] (heptyl) anilino}propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy](heptyl) anilino}propanoate;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl heptyl
- 10 carboxamido)phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl heptyl
- carboxamido)phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl heptyl
- carboxamido)phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- 15 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl]
- 20 phenoxy}-2-methyl propanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- 25 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido) phenoxy]-2-methyl propanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido)
- 30 phenoxy]-2-methyl propanoic acid or its salts;


- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido)phenoxy]-2-methyl propanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;
- 5 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-
- 10 methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid or its salts;
- 15 (±) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy} pentanoic acid or its salts;
- (+) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy} pentanoic acid or its salts;
- (-) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}
- 20 pentanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;
- 25 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)
- 30 carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts;

- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoic acid or its salts;
- 5 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- 10 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- 15 (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]methyl pentanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]methyl pentanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]methyl pentanoic acid or its salts;
- 20 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- 25 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}pentanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}pentanoic acid or its salts;
- 30

- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- 5 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- 10 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- 15 (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoic acid or its salts;
- 20 (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- 25 (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid or its salts;
- 30


- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenylsulfanyl}-2-methyl butanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- 5 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- 10 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- 15 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- 20 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid or its salts;
- 25 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid or its salts;

According to another embodiment of the present invention there is provided a process for the preparation of the compound of formula (I) where all the symbols are as defined earlier which comprises, reacting a compound of formula (IIIa)



(IIIa)

where R¹, R², R³ and X are as defined above with a compound of general formula (IIIb)




5 where L¹ is a leaving group and all other symbols are as defined earlier to produce a compound of formula (I) where all symbols are as defined earlier.


The leaving group represented by L¹ in formula (IIIb) may be halogen atom like chlorine, bromine or iodine or other leaving groups such as p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like,

10 The reaction of compound of formula (IIIa) with a compound of formula (IIIb) where all symbols are as defined earlier to produce a compound of formula (I) where all symbols are as defined earlier may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof. The reaction may be carried out in an inert atmosphere which
 15 may be maintained by using inert gases such as N₂, Ar, He and the like. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide, potassium hydroxide, alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide or
 20 mixtures thereof. The amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (IIIa), preferably the amount of base ranges from 1 to 3 equivalents. The reaction may be carried out at a temperature in the range of 0°C to 150°C, preferably at a temperature in the range of 15°C to 100°C. The duration of the reaction may range from 0.25 to 24 hours, preferably from 0.25 to 12
 25 hours.

In yet another embodiment of the present invention, there is provided a process for the preparation of compound of formula (I) where all the symbols are as defined earlier, which comprises, reacting a compound of formula (IIIc)




- 5 where L^2 represents a halogen atom such as Cl, Br or I, W represents C=O and all other symbols are as defined earlier with a compound of formula (IIIId)



where all symbols are as defined earlier.


- The reaction of compound of the formula (IIIc) with a compound of formula (IIIId) where all symbols are as defined earlier to produce a compound of formula (I) defined above may be carried out in the presence of solvents such as dioxane, DME, carbon disulfide, nitrobenzene and the like or mixtures thereof. The reaction may be carried out in the presence of a catalyst such as FeCl_3 , AlCl_3 , I_2 , ZnCl_2 , iron and the like. The reaction may be carried out in inert atmosphere which may be maintained by using inert gases such as N_2 , Ar, He and the like. The reaction temperature may range from 25 °C to 180 °C. The reaction time may range from 1 to 24 hours.

In still another embodiment of the present invention there is provided a process for the preparation of compound of formula (I) defined above which comprises, reacting a compound of formula (IIIe)



20

where L^1 is a leaving group and all other symbols are as defined earlier with a compound of formula (IIIId)




where all symbols are as defined earlier.


The leaving represented by L^1 in formula (IIIe) may be halogen atom like chlorine, bromine or iodine or other leaving groups such as p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like.

The reaction of compound of formula (IIIe) with compound of formula (III f) to produce a compound of the formula (I) defined above may be carried out in the presence of aprotic solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N_2 , Ar, He and the like. The reaction may be effected in the presence of a base such as K_2CO_3 , Na_2CO_3 or NaH or mixtures thereof. Acetone may be used as solvent when Na_2CO_3 or K_2CO_3 is used as a base. The reaction temperature may range from 0°C - 120°C , preferably at a temperature in the range of 30°C - 100°C . The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 12 hours.

In yet another embodiment of the present invention, there is provided a process for the preparation of compound of formula (I), where W represents NR^7 and all other symbols are as defined above, which comprises, reacting the compound of formula (IIIg)




where L^3 is a leaving group such as halogen atom, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, or L^3 represents COOH , COCl , with compound of formula (IIIh)



where all symbols are as defined above.

The reaction of compound of formula (IIIg) with compound of formula (IIIh) where all symbols are as defined earlier to produce a compound of the formula (I) defined above may be carried out in the presence of aprotic solvents such as THF, DMF, DMSO, DME, DCM, CHCl_3 and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N_2 , Ar, He and the like. The reaction may be effected in the presence of a base such as K_2CO_3 , Na_2CO_3 or NaH, KH, triethyl amine and the like or mixtures thereof or diisopropyl carbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC), diisopropyl azodicarboxylate (DIAD), DEAD when L^3 is a COOH or COCl. The reaction temperature may range from 0°C – 120°C , preferably at a temperature in the range of 25°C – 100°C . The duration of the reaction may range from 1 to 72 hours, preferably from 2 to 24 hours.


In yet another embodiment of the present invention, there is provided a novel intermediate of formula (IIIh)




wherein n is from 0-4; W represents NR^7 , where R^7 represents hydrogen, $(\text{C}_1\text{-C}_{12})$ alkyl, aryl, or aralkyl group; Ar represents substituted or unsubstituted divalent single or fused aromatic or heterocyclic group; R^4 and R^5 may be same or different and represent hydrogen, hydroxy, alkoxy, halogen or substituted or unsubstituted groups selected from $(\text{C}_1\text{-C}_{12})$ alkyl, aralkyl or heteroaralkyl groups; R^6 may be hydrogen or substituted or unsubstituted groups selected from $(\text{C}_1\text{-C}_{12})$ alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents oxygen or NR^8 , where R^8 represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; R^6 and R^8 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, one or two nitrogen atoms and may optionally contain one or more heteroatoms selected from oxygen, or sulfur; Q represents O, S, SO, SO_2 or NR^9 wherein R^9 represents hydrogen, substituted or unsubstituted groups selected from $(\text{C}_1\text{-C}_{12})$ alkyl, cycloalkyl, aryl, hydroxyalkyl,

aralkyl, heterocyclyl, heteroaryl, or heteroaralkyl groups; and p is an integer of 0 or 1.

The compound of formula (IIIh) where all symbols are as defined above may be prepared by reacting a compound of formula (IIIi)



where all symbols are as defined above with compound of formula (IIIj)



where L^1 is a leaving group and all other symbols are as defined above

The reaction of compound of formula (IIIi) with a compound of formula (IIIj) to produce a compound of the formula (IIIh) may be carried out in the presence of solvents such as THF, DMF, DMSO, DME, acetonitrile and the like or mixtures thereof. The reaction may be effected in the presence of a base such as K_2CO_3 , Na_2CO_3 , NaOH , KOH , NaOEt , K^+BuO^- , NaH and the like. The reaction temperature may range from 0°C - 120°C , preferably at a temperature in the range of 30°C - 100°C . The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 12 hours.

It is appreciated that in any of the above-mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl, triphenyl methyl, benzyloxycarbonyl, tetrahydropyran(THP) etc, to protect hydroxyl or phenolic hydroxy group; N-tert-butoxycarbonyl (N-Boc), N-benzyloxycarbonyl (N-Cbz), N-9-fluorenyl methoxy carbonyl (-N-FMOC), benzophenoneimine, propargyloxy carbonyl (POC) etc, for protection of amino or anilino group, acetal protection for aldehyde, ketal protection for ketone and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.

The pharmaceutically acceptable salts are prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium hydroxide, potassium t-butoxide, calcium

hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol etc. Mixtures of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guanidine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixtures of solvents may also be used.

The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the compound of formula (I) where YR^6 represents OH may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula (I) may be prepared by hydrolyzing the pure diastereomeric amide.

Various polymorphs of a compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heating or melting the

compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.

The present invention provides a pharmaceutical composition, containing the
5 compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers, diluents and the like, useful for the treatment and / or prophylaxis of diseases such as hypertension,
10 coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders. These compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, VLDL and LDL. The compounds of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis,
15 nephrotic syndrome, hypertensive nephrosclerosis, nephropathy. The compounds of general formula (I) are also useful for the treatment and or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease, and other cardiovascular disorders. These
20 compounds may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, as inflammatory agents, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, retinopathy, arteriosclerosis, xanthoma and for the treatment
25 of cancer. The compounds of the present invention are useful in the treatment and / or prophylaxis of the above said diseases in combination / concomitant with one or more HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as ezetimibe, orlistat, fibrate, fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol or their combination. The compounds of the
30 present invention in combination with HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents can be administered together or within such a period to act synergistically or additively. The HMG CoA reductase inhibitors

may be selected from those used for the treatment or prevention of hyperlipidemia such as lovastatin, provastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin and their analogs thereof. Suitable fibric acid derivative may be gemfibrozil, clofibrate, fenofibrate, ciprofibrate, benzafibrate and their analogs thereof.

5 The present invention also provides a pharmaceutical compositions, containing one or more of the compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed
10 carriers, diluents and the like.

 The present invention also provides a pharmaceutical composition, containing one or more of the compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or their pharmaceutically
15 acceptable solvates and one or more HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibric acid derivatives, fibrates, nicotinic acid, cholestyramine, colestipol, probucol, ezetimibe and orlistat in combination with the usual pharmaceutically employed carriers, diluents and the like.

 The pharmaceutical composition of this invention may be in the forms
20 normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being
25 pharmaceutically acceptable carriers, diluents or solvents.

 Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the
30 compounds can be combined with a suitable solid, liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions, may, if desired, contain additional components such as


flavorants, sweeteners, excipients and the like. For parenteral administration, the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

The compound of the formula (I) as defined above are clinically administered to mammals, including man, via either oral or parenteral routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.01 to about 50 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight per day administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.

The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.

Preparation 1

Ethyl 2-methyl-2-(4-nitrophenoxy)propanoate



To a stirred solution of 4-Nitro phenol (2 g, 14.0 mmol) in ethanol (40 ml) was added potassium hydroxide (2.4 g) and stirred for 10 min. To this ethyl 2-bromo isobutyrate (4.2 g, 21 mmol) was added and the mixture heated to reflux for 15 h. The mixture, was filtered, washed with EtOAc and the combined filtrates were added to water

(100 ml) and extracted with EtOAc. The combined organic layers were washed with water, 50% sodium carbonate solution and then with brine. The organic layer was dried over Na_2SO_4 and evaporated under reduced pressure to give the title compound as a thick gummy mass (2 g, 56%).

- 5 ^1H NMR (200 MHz, CDCl_3): δ 8.13 (d, $J=9.28\text{Hz}$, 2H), 6.83 (d, $J=9.28\text{Hz}$, 2H), 4.21 (q, $J=4.21\text{ Hz}$, 2H), 1.92 (s, 6H), 1.21 (t, 4.21Hz , 3H).


The compounds given in Table I were also prepared using a similar method described in preparation 1.

TABLE I

Prep. No.	Structure	Mp, Yield, Nature	^1H NMR (CDCl_3): δ
2		Liquid, 30%	8.14 (d, $J=9.28\text{Hz}$, 2H), 6.85 (d, $J=9.28\text{Hz}$, 2H), 4.23 (q, $J=7.33\text{Hz}$, 2H), 2.11-1.96 (m, 2H), 1.22 (s, 3H), 1.26 (t, $J=6.84\text{ Hz}$, 3H), 0.98 (t, $J=7.33\text{ Hz}$, 3H).
3		Gummy liquid, 92%	8.20 (d, $J=9.28\text{Hz}$, 2H), 6.93 (d, $J=9.28\text{Hz}$, 2H), 4.72 (t, $J=6.35\text{Hz}$, 1H), 4.23 (q, $J=6.84\text{Hz}$, 2H), 2.10-1.90 (m, 2H), 1.65 -1.50 (m, 2H), 1.26 (t, $J=6.84\text{Hz}$, 3H), 0.99 (t, $J=7.33\text{Hz}$, 3H).
4		70-72 °C, 50%	6.78 (d, $J=8.79\text{Hz}$, 2H), 6.68 (d, $J=8.79\text{Hz}$, 2H), 4.24 (q, $J=6.84\text{Hz}$, 2H), 1.52 (s, 6H), 1.27 (t, $J=6.84\text{Hz}$, 3H).
5		68 °C, 26%	6.79 (d, $J=9.28\text{Hz}$, 2H), 6.69 (d, $J=9.28\text{Hz}$, 2H), 4.71 (bs, 1H, D_2O exchangeable), 4.25 (q, $J=7.33\text{Hz}$, 2H), 1.94 (q, $J=7.32\text{Hz}$, 2H), 1.42 (s, 3H), 1.28 (t, $J=7.33\text{Hz}$, 3H), 0.98 (t, $J=7.32\text{Hz}$, 3H).
6			8.00 (d, $J=8.79\text{Hz}$, 2H), 8.79 (d, $J=8.79\text{ Hz}$, 2H), 4.23 (q, $J=7.33\text{Hz}$, 2H), 1.66 (s, 6H), 1.22 (t, $J=7.33\text{ Hz}$, 3H).

10

Preparation 7

Ethyl-2-methyl-2-(4-amino phenyloxy)propanoate


The title compound (1.2 g, 68%) was prepared from ethyl 2-methyl-2-(4-nitrophenyloxy)propanoate (2 g, 7.9 mmol) by hydrogenation with 10% Pd/C (1 g) in methanol at 50 psi and room temperature for 2 h.

¹H NMR (CDCl₃, 200MHz): δ 6.75 (d, J=8.30Hz, 2H), 6.57 (d, J=8.30Hz, 2H), 4.23 (q, J=6.84Hz, 2H), 1.52 (s, 6H), 1.29 (t, J=6.84Hz, 3H).

The compounds given in Table II were also prepared using a similar method described in preparation 7.

TABLE II

Prep No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
8		Liquid, 79%	6.75 (d, J=8.79Hz, 2H), 6.58 (d, J=8.79 Hz, 2H), 4.25 (q, J= 6.84Hz, 2H), 1.93 (q, J=7.33Hz, 2H), 1.41 (s, 3H), 1.30 (t, J=6.84Hz, 3H), 0.98 (t, J=7.33Hz, 3H).
9		Liquid, 97%	6.76 (d, J=8.79Hz, 2H), 6.69 (d, J=8.79Hz, 2H), 4.48 (t, J=5.86Hz, 1H), 4.20 (q, J=6.84Hz, 2H), 3.78 (bs, 2H, D ₂ O exchan geable), 1.96-1.83 (m, 2H), 1.61-1.44 (m, 2H), 1.25 (t, J=6.84 Hz, 3H), 0.97 (t, J=7.33 Hz, 3H).

Preparation 10**Ethyl-2-(4-amino phenyloxy)octanoate**





To suspension of sodium hydride (0.458 g, 19.08 mmol) in dry DMF (10 ml) p-aminophenol (1 g, 9.174 mmol) in dry DMF (10 ml) was added at 0 °C and stirred



at that temperature for 15 min. To this ethyl-2-bromo octanoate (3.454 g, 13.7 mmol) was added and stirred the mixture at room temperature for 12 h. The reaction mixture was quenched with ice and added water (100 ml) and extracted with EtOAc (50 X 3 mL). The combined extracts were washed with water, brine and dried over Na₂SO₄ to give the title compound (0.4 g, 16%).


¹H NMR (CDCl₃, 200MHz): δ 6.74 (d, J=8.79Hz, 2H), 6.62 (d, J=8.79Hz, 2H), 4.46 (t, J=6.35Hz, 1H), 4.20 (q, J=6.83Hz, 2H), 3.48 (bs, 2H, D₂O exchangeable), 2.00-1.82 (m, 2H), 1.60-1.21 (m, 11H), 0.89 (t, J=5.86Hz, 3H).

The compounds given in Table III were also prepared using a similar method described in preparation 10.

TABLE III

Prep No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
11		Gummy oil, 40%	6.655 (d, J=9.28Hz, 2H), 6.55 (d, J=9.28Hz, 2H), 4.21 (q, J=6.83Hz, 2H), 1.50 (s, 6H), 1.27 (t, J=6.83Hz, 3H).
12		Gummy, 25%	7.28 (d, J=8.30Hz, 2H), 6.61 (d, J=8.30Hz, 2H), 4.11 (q, J=7.33Hz, 2H), 3.76 (bs, 2H, D ₂ O exchangeable), 3.44 (t, J=7.33Hz, 1H), 1.91-1.57 (m, 2H), 1.49-1.32 (m, 2H), 1.20 (t, 7.33Hz, 3H), 0.921 (t, 7.33Hz, 3H).
13		Gummy, 69%	7.27 (d, J=8.30Hz, 2H), 6.59 (d, J=8.30Hz, 2H), 3.77 (bs, 2H, D ₂ O exchangeable), 3.19 (d, J=8.79Hz, 1H), 2.10-1.95 (m, 1H), 1.22-1.12 (m, 6H), 0.99 (d, J=6.35Hz, 3H).
14		Gummy, 68%	7.26 (d, J=8.30Hz, 2H), 6.59 (d, J=8.30Hz, 2H), 4.10 (q, J=7.32Hz, 2H), 3.78 (bs, 2H, D ₂ O exchangeable), 3.34 (t, J=7.52Hz, 1H), 1.90-1.63 (m, 2H), 1.19 (t, J=7.32Hz, 3H), 0.99 (t, 7.32Hz, 3H).

Prep No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
15		Gummy, 72%	J=7.53Hz, 3H). 7.26 (d, J=8.30Hz, 2H), 6.60 (d, J=8.30Hz, 2H), 4.08 (q, J=7.33Hz, 2H), 3.80 (bs, 2H, D ₂ O exchangeable), 3.50 (t, J=6.84Hz, 1H), 1.81-1.43 (m, 3H), 1.18 (t, J=7.33Hz, 3H), 0.91 (d, J=1.95Hz, 3H), 0.88 (d, J=1.95Hz, 3H).
16		Gummy, 56%	7.032(d, J=8.79Hz, 2H), 6.70 (d, J=8.79Hz, 2H), 6.09 (s, 1H, D ₂ O exchangeable), 4.12 (q, J=7.32 Hz, 2H), 3.25 (d, J=9.27 Hz, 2H), 2.10-1.95 (m, 1H), 1.29-1.15 (m, 6H), 1.00 (d, J=6.84 Hz, 3H).

Preparation 17**Ethyl-3-methyl-2-(4-heptylamino phenylthio)butanoate**





- 5 To ethyl-3-methyl-2-(4-amino phenylthio)octanoate obtained from preparation 13, (2.57 g, 0.01015 mol) was added K₂CO₃ (2.8 g, 0.02 mol), tetrabutyl ammonium bromide (TBAB) (3.27 g, 0.01 mol), heptylbromide (1.756 ml, 0.011 mol) in toluene (50 ml) and heated at 100 °C for 16 h. The reaction mixture was cooled to room temperature, filtered and washed with EtOAc (100 ml). The
- 10 combined organic layers were washed with water, brine and dried over Na₂SO₄ and concentrated under reduced pressure. The crude compound was purified by column chromatography, using 1:2 EtOAc : pet. ether as eluent to give the title compound (2.4 g, 67.4%).


^1H NMR (CDCl_3 , 200MHz): δ 7.28 (d, $J=8.79\text{Hz}$, 2H), 6.49 (d, $J=8.79\text{Hz}$, 2H), 4.09 (q, 7.32Hz , 2H), 3.74 (bs, 1H, D_2O exchangeable), 3.18 (d, $J=9.28\text{Hz}$, 1H), 3.08 (t, $J=7.32\text{ Hz}$, 2H), 2.13-1.95 (m, 1H), 1.60-1.51 (m, 2H), 1.31-1.13 (m, 14H), 0.99 (d, $J=6.83\text{Hz}$, 3H), 0.89 (t, $J=6.84\text{Hz}$, 3H).


- 5 The compounds given in Table IV were also prepared using a similar method described in Preparation 17.

10

TABLE IV

Prep No.	Structure	Mp, Yield, Nature	^1H NMR (CDCl_3): δ
18		Liquid, 50%	7.28 (d, $J=7.3\text{ Hz}$, 2H), 6.50 (d, $J=7.30\text{ Hz}$, 2H), 4.11 (q, $J=7.3\text{ Hz}$, 2H), 3.33 (t, $J=6.83\text{ Hz}$, 1H), 3.08 (t, $J=6.84\text{ Hz}$, 2H), 1.87-1.57 (m, 4H), 1.4-1.2 (m, 11H), .99 (t, $J=7.33\text{ Hz}$, 3H), 0.89 (t, $J=6.35\text{ Hz}$, 3H).
19		Liquid, 33%	7.26 (d, $J=8.3\text{ Hz}$, 2H), 6.49 (d, $J=8.3\text{ Hz}$, 2H), 4.08 (q, $J=6.84\text{ Hz}$, 2H), 3.47 (t, $J=7.84\text{ Hz}$, 1H), 3.08 (t, $J=6.84\text{ Hz}$, 2H), 1.80-1.45 (m, 6H), 1.40-1.10 (m, 11H), 1.00-0.89 (m, 9H).
20		Liquid, 33%	6.77 (d, $J=8.79\text{ Hz}$, 2H), 6.48 (d, $J=8.79\text{ Hz}$, 2H), 4.23 (q, $J=7.33\text{ Hz}$, 2H), 3.04 (t, $J=6.83\text{ Hz}$, 2H), 1.6-1.50 (m, 19H), 0.88 (t, $J=6.35\text{ Hz}$, 3H).
21		Liquid, 32%	6.77 (d, $J=8.79\text{ Hz}$, 2H), 6.55 (d, $J=8.79\text{ Hz}$, 2H), 4.46 (t, $J=6.45\text{ Hz}$, 1H), 4.20 (q, $J=6.8\text{ Hz}$, 2H), 3.04 (t, $J=7.04\text{ Hz}$, 2H), 1.95-1.82 (m, 2H), 1.57-1.45 (m, 4H), 1.42-1.2 (m, 11H), 1.05-0.8 (m, 6H).


Prep No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
22		Liquid, 66%	6.77 (d, J=8.79 Hz, 2H), 6.48 (d, J=8.79 Hz, 2H), 4.24 (q, J=7.32 Hz, 2H), 3.04 (t, J=6.83 Hz, 2H), 1.92 (q, J=7.33 Hz, 2H), 1.60-1.40 (m, 4H), 1.98-1.15 (m, 11H), 0.97 (t, J=7.33 Hz, 3H), 0.88 (t, J=6.35 Hz, 3H).

Preparation 23**2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid**

- 5 To a suspension of NaH (1.25 g, 0.04 mol) in dry DMF (100 mL) 2-ethyl-4-phenyl-4(3H)pyrimidinone (4 g, 0.02 mol) was added at 0°C and stirred for 30 min. To this anhydrous LiBr (2.5 g, 0.024 mol) was added at 0°C and stirred at RT for further 10 min. Ethyl bromoacetate (4 g, 0.024 mol) was added and the mixture was heated to 80°C for 16 h. The reaction mixture was quenched with ice-water,
- 10 extracted with EtOAc and the combined layers were washed with water, brine and dried over Na₂SO₄ to get 'O' and 'N' alkyl mixtures (a mixture of O-alkylated product and N-alkylated product), which were separated by column chromatography using 30% EtOAc : pet. ether as eluent to yield 'N' alkylated compound, ethyl-2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetate (2.8 g, 49%) as a solid. The
- 15 N-alkylated compound as hydrolyzed using aq. NaOH (2.8 g, 5 ml of H₂O) in methanol (15 ml) at RT for 2 h to give the title compound as white solid (mp : 201-203 °C, (2.3 g, 91%).

¹H NMR (CDCl₃ + CD₃OD, 200MHz): δ 8.04-7.99 (m, 2H), 7.68-7.40 (m, 3H), 6.80 (s, 1H), 4.87 (s, 2H), 4.82 (q, J=7.32Hz, 2H), 1.40 (t, J=7.32Hz, 3H).

20 Preparation 24**2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)ethylamine**




To a suspension of 60% NaH (0.625 g, 0.026 mol) in DMF (30 mL), 2-ethyl-4-phenyl-4(3H)pyrimidinone (2 g, 0.01 mol) was added at 0 °C and stirred at RT for 30 min. The reaction mixture was cooled to 0 °C and added LiBr (1.7 g, 0.0195 mol) and the temperature was raised to RT and added 2-benzyloxycarbonyl amino ethylbromide (2.58 g, 0.01 mol) and tetrabutyl ammonium bromide (3.3 g, 0.01 mol), and heated at 80 °C for 16 h. The reaction mixture was quenched with ice-water, extracted with EtOAc, washed with water, brine and dried over Na₂SO₄, concentrated the solvent to give 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)N-benzyloxycarbonyl aminoethyl bromide (1.1 g, 30%). This compound was hydrogenated over 10% Pd/C with ethanol as the solvent at 1 atm pressure of H₂ gas, filtered and evaporated the solvent to give the title compound (0.48 g, 98%) as a liquid.

¹H NMR (CDCl₃, 200MHz): δ 8.08-8.037 (m, 2H), 7.48-7.32 (m, 3H), 6.81 (s, 1H), 4.17 (t, J=7.32Hz, 2H), 3.03-2.87 (m, 4H), 1.39 (t, J=8.30Hz, 3H)

Preparation 25

2-Ethyl-1-[2-(4-hydroxyphenylsulfanyl)ethyl]-4-phenyl-1,6-dihydropyrimidin-6-one



To 4-hydroxy thiophenol (2.016 g, 0.016 mol) in DMF (50 ml) K₂CO₃ (4.416 g, 0.032 mol) was added and stirred for 30 min. and then added 1-(2-chloroethyl)-2-ethyl-4-phenyl-1,6-dihydropyrimidin-6-one (4.3 g, 0.016 mol). The resulting mixture was stirred at room temperature for 15 h, filtered, washed with EtOAc and the combined filtrates were partitioned between water and EtOAc. The EtOAc layer was washed with water, brine, dried over Na₂SO₄ and evaporated the solvent to get the title compound as a gummy mass (1.25 g, 26%).


¹H NMR (CDCl₃, 200MHz): δ 9.64 (s, 1H, D₂O exchangeable), 8.08-8.05 (m, 2H), 7.50-7.35 (m, 3H), 7.27 (d, J=9.28Hz, 2H), 6.83 (s, 3H), 6.76 (d, J=9.28Hz, 2H), 4.08 (t, J=81Hz, 2H), 3.11 (t, J=7.81Hz, 2H), 2.72 (q, J=6.84Hz, 2H), 1.22 (t, J=7.32Hz, 3H).

5

10

Example 1

Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-3-methyl butanoate



15

To a mixture of 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid obtained from preparation 23, (1.77 g, 6.89 mmol), ethyl-3-methyl-2-(4-heptylamino phenylthio)butanoate, obtained from preparation 17, (2.2 g, 6.26 mmol) and HOBt (0.85 g, 6.89 mmol) in dry DCM (30 mL) was added N,N-diisopropyl carbodiimide (DIC) (1.72 mL, 6.89 mmol) at RT and stirred at that temperature for 24 h. The reaction mixture was diluted with more DCM (100 mL) and washed with water, saturated NaHSO₄ solution, brine and the DCM layer was dried over Na₂SO₄ and evaporated the solvent. The crude ester was purified over silica gel column by eluting with 20% EtOAc : pet. ether to obtain the title compound as gummy mass (1.8 g, 49%).




25

¹H NMR (CDCl₃, 200MHz): δ 8.02-7.97 (m, 2H), 7.55 (d, J=8.30Hz, 2H), 7.46 - 7.42 (m, 3H), 7.32 (d, 2H), 6.75 (s, 1H), 4.49 (s, 2H), 4.17 (q, J=6.84Hz, 2H), 4.17 (q, J=6.84Hz, 2H), 3.69 (t, J=7.32Hz, 2H), 3.51 (d, J=8.31Hz, 1H), 2.70 (q,





J=7.33Hz, 2H), 2.24-2.13 (m, 1H), 1.40-1.20 (m, 2H), 1.35 (t, J=7.33Hz, 3H), 1.25-1.06 (m, 17H), 0.85 (t, J=6.83Hz, 3H).


The compounds given in Table V were also prepared using a similar method described in Example 1.

5 **TABLE V**

Exam. No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
2		148-150 °C, 20%	8.1-7.98 (m, 2H), 7.70 (d, J=8.79 Hz, 2H), 7.50-7.4 (m, 3H), 6.84 (d, J=8.79 Hz, 2H), 6.83 (s, 1H), 4.38 (t, J=5.86 Hz, H), 4.22 (q, J=6.84 Hz, 2H), 3.79 (t, J=5.86 Hz, 2H), 2.97 (q, J=7.33 Hz, 2H), 1.45 (t, J=7.33 Hz, 3H), 1.36 (s, 3H), 1.30 (s, 3H), 1.26 (t, J=6.84 Hz, 3H).
3		Liquid, 54%	8.10-7.95 (m, 2H), 7.5-7.4 (m, 3H), 7.28 (d, J=8.30 Hz, 2H), 6.84 (d, J=8.3 Hz, 2H), 6.78 (s, 1H), 4.36 (t, J=5.84 Hz, 2H), 4.23 (q, J=7.3 Hz, 2H), 3.71 (t, J=5.84 Hz, 2H), 3.28 (t, J=6.83 Hz, 2H), 3.08 (q, J=6.84 Hz, 2H), 1.62 (s, 6H), 1.5-1.3 (m, 2H), 1.28-1.0 (m, 14H), 0.84 (t, J=6.32 Hz, 3H).
4		128-130°C, 54%	8.89 (s, 1H, D ₂ O exchangeable), 8.10-8.00 (m, 2H), 7.50-7.45 (m, 3H), 7.38 (d, J=8.79 Hz, 2H), 6.87 (s, 1H), 6.81 (d, J=8.79 Hz, 2H), 4.85 (s, 2H), 4.22 (q, J=6.84 Hz, 2H), 3.08 (d, J=7.32 Hz, 2H), 1.55 (s, 6H), 1.45 (t, J=7.32 Hz, 3H), 1.25 (t, J=6.84 Hz, 3H).


Exam. No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
5		Liquid, 55%	8.02-7.95 (m, 2H), 7.45-7.40 (m, 3H), 7.24 (d, J=8.30 Hz, 2H), 6.74 (s, 1H), 4.48 (s, 2H), 4.26 (q, J=7.33 Hz, 2H), 3.66 (t, J=6.84 Hz, 2H), 2.68 (q, J=7.32 Hz, 2H), 1.64 (s, 6H), 1.37 (q, J=7.32 Hz, 2H), 1.25-1.10 (m, 16H), 0.85 (t, J=5.86 Hz, 3H).
6		Liquid, 47%	8.10-8.00 (m, 2H), 7.60 (d, J=8.31 Hz, 2H), 7.50-7.40 (m, 3H), 7.36 (d, J=8.31 Hz, 2H), 6.78 (s, 1H), 4.48 (s, 2H), 4.16 (q, J=6.84 Hz, 2H), 3.76 (t, J=6.84 Hz, 2H), 2.70 (q, J=7.33 Hz, 2H), 1.61 (s, 6H), 1.38 (t, J=7.33 Hz, 3H), 1.25 (t, J=6.84 Hz, 3H), 1.20 - 1.00 (m, 10H), 0.84 (t, J=6.94 Hz, 3H).
7		Liquid, 47%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.26 (d, J=8.30 Hz, 2H), 6.95 (d, J=8.30 Hz, 2H), 6.78 (s, 1H), 4.50 (s, 2H), 4.28 (q, J=6.84 Hz, 2H), 3.67 (t, J=7.33 Hz, 2H), 2.69 (q, J=7.32 Hz, 2H), 2.04 (q, J=7.32 Hz, 2H), 1.58 (s, 3H), 1.39 (t, J=7.32 Hz, 3H), 1.30-1.10 (m, 13H), 1.02 (t, J=7.32 Hz, 3H), 0.86 (t, J=5.37 Hz, 3H).
8		Liquid, 47%	8.05-7.97 (m, 2H), 7.56 (d, J=8.30 Hz, 2H), 7.47-7.40 (m, 3H), 7.34 (d, J=8.30 Hz, 2H), 7.27 (s, 1H), 4.50 (s, 2H), 4.18 (q, J=6.83 Hz, 2H), 3.80-3.60 (m, 3H), 2.71 (q, J=6.84 Hz, 2H), 2.40-2.15 (m, 2H), 2.10-1.50 (m, 4H), 1.39 (t, J=6.84 Hz, 3H), 1.35-1.10

Exam. No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
			(m, 11H), 0.99-0.70 (m, 6H).
9		140-143 °C, 30%	8.91(s, 1H, D ₂ O exchangeable), 8.10-8.00 (m, 2H), 7.50-7.46 (m, 3H), 7.41 (d, J=8.79 Hz, 2H), 6.87 (s, 1H), 6.81 (d, J=8.79 Hz, 2H), 4.85 (s, 2H), 4.53 (t, J=6.35 Hz, 1H), 4.19 (q, J=7.33 Hz, 2H), 3.07 (d, J=7.33 Hz, 2H), 2.05-1.85 (m, 2H), 1.44 (t, J=7.33 Hz, 3H), 1.35-1.15 (m, 11H), 0.85 (t, J=4.99 Hz, 3H).
10		Liquid, 35%	8.05-8.00 (m, 2H), 7.57 (d, J=8.31 Hz, 2H), 7.50-7.40 (m, 3H), 7.33 (d, J=8.31 Hz, 2H), 6.75 (s, 1H), 4.49 (s, 2H), 4.18 (q, J=7.32 Hz, 2H), 3.80-3.60 (m, 3H), 2.70 (q, J=7.33 Hz, 2H), 2.05 - 1.80 (m, 2H), 1.60 - 1.58 (m, 2H), 1.30-1.20 (m, 14H), 1.07 (t, J=7.33 Hz, 3H), 0.85 (t, J=6.34 Hz, 3H)..
11		Gummy oil, 22%	8.05-7.95 (m, 2H), 7.55 (d, J=8.79 Hz, 2H), 7.50-7.40 (m, 3H), 7.33 (d, J=8.79 Hz, 2H), 6.74 (s, 1H), 4.49 (s, 2H), 4.15 (q, J=7.33 Hz, 2H), 3.79 (t, J=8.30 Hz, 1H), 3.69 (t, J=7.82 Hz, 2H), 2.70 (q, J=6.84 Hz, 2H), 2.30-2.20 (m, 1H), 1.90-1.60 (m, 2H), 1.60-1.50 (m, 2H), 1.45-1.10 (m, 17H), 1.00-0.8(m, 6H).
12		Liquid, 22%	8.02-7.95 (m, 2H), 7.50-7.35 (m, 3H), 7.26 (d, J=8.79 Hz, 2H), 6.95 (d, J=8.79 Hz, 2H), 6.73 (s, 1H), 4.61 (t, J=5.38 Hz,

Exam. No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
			1H), 4.47 (s, 2H), 4.23 (q, J=7.32 Hz, 2H), 3.64 (t, J=7.32 Hz, 2H), 2.68 (q, J=7.33 Hz, 2H), 2.00-1.80 (m, 2H), 1.60-1.40 (m, 2H), 1.36 (t, J=7.33 Hz, 3H), 1.30-1.10 (m, 13H), 0.98 (t, J=7.33 Hz, 3H), 0.82 (t, J=6.80 Hz, 3H).
13		Liquid, 22%	8.05-7.95 (m, 2H), 7.50-7.30 (m, 7H), 6.86 (s, 1H), 4.84 (s, 2H), 4.08 (q, J=8.29 Hz, 2H), 3.28 (d, J=8.29 Hz, 1H), 3.05 (q, J=6.84 Hz, 2H), 2.10-1.95 (m, 1H), 1.43 (t, J=7.33 Hz, 3H), 1.30-0.95 (m, 9H).

Example 14

Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoate



5




To a solution of ethyl-2-methyl-4-hydroxy phenoxy propanoate (454.6mg, 1.863mmol) (obtained from preparation 4) in dry DMF (10 mL) was added K₂CO₃ (514 mg, 3.726 mmol) and stirred at RT for 30 min. To this 1-(2-chloroethyl)-2-ethyl-4-phenyl-1,6-dihydro-6-pyrimidinone (489 mg, 1.863 mmol) in DMF (5 mL) was added and the resulting mixture was stirred at 80 °C for 12 h. The reaction mixture was filtered, diluted with EtOAc (100 mL) and washed with water, brine and dried over Na₂SO₄. The solvent was evaporated and purified by column chromatography by eluting with 20% EtOAc : pet. ether to give the title compound as a white solid (mp : 80-82 °C, 226 mg, 27%).




10


^1H NMR (CDCl_3 , 200MHz): δ 8.03 –8.00 (m, 2H), 7.47-7.43 (m, 3H), 6.85 (d, $J=9.28\text{Hz}$, 2H), 6.78 (s, 1H), 6.71 (d, $J=9.28\text{Hz}$, 2H), 4.46 (t, $J=4.89$, 2H), 4.27 (q, $J=8.81\text{Hz}$, 2H), 4.20 (t, $J=4.89\text{Hz}$, 2H), 3.08 (q, $J=7.32\text{Hz}$, 2H), 1.51 (s, 6H), 1.40 (t, $J=7.32\text{Hz}$, 3H), 1.26 (t, $J=8.81\text{Hz}$, 3H).

- 5 The compounds given in Table VI were also prepared using a similar method described in Example 14.

TABLE VI


Exam No.	Structure	Mp, Yield, Nature	^1H NMR (CDCl_3): δ
15		Liquid, 20%	8.05-7.95(m, 2H), 7.50-7.40 (m, 3H), 6.82(s, 1H), 6.80 (d, $J=9.28\text{Hz}$, 2H), 6.70 (d, $J=9.28\text{Hz}$, 2H), 4.45 (t, $J=4.88\text{Hz}$, 2H), 4.25 (t, $J=4.88$, 2H), 4.21 (q, $J=7.32\text{Hz}$, 2H), 3.07 (q, $J=7.33\text{Hz}$, 2H), 1.90 (q, $J=7.32\text{Hz}$, 2H), 1.60 (s, 3H), 1.43 (t, $J=7.33\text{Hz}$, 3H), 1.25 (t, $J=7.32\text{Hz}$, 3H), 0.95 (t, $J=7.32\text{Hz}$, 3H).
16		80-82 °C, 20%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 6.80 (d, $J=9.27\text{Hz}$, 2H), 6.75 (d, $J=9.27\text{Hz}$, 2H), 6.73 (s, 1H), 4.52-4.40 (m, 1H), 4.45 (t, $J=4.88\text{Hz}$, 2H), 4.26 (t, $J=4.88\text{Hz}$, 2H), 4.18 (q, $J=6.84\text{Hz}$, 2H), 3.08 (q, $J=7.33\text{Hz}$, 2H), 1.95-1.80 (m, 2H), 1.60-1.50 (m, 2H), 1.44 (t, $J=7.32\text{Hz}$, 3H), 1.23 (t, $J=6.84\text{Hz}$, 3H), 0.95 (t, $J=6.34\text{Hz}$, 3H).
17		Liquid, 47%	8.05-8.00 (m, 2H), 7.55-7.40 (m, 3H), 7.31 (d, $J=8.30\text{Hz}$, 2H), 6.81 (s, 1H), 6.58 (d, $J=8.30\text{Hz}$, 2H), 4.33 (t, $J=5.86\text{Hz}$, 2H), 4.09 (q, $J=7.32\text{Hz}$, 2H), 3.54 (t, $J=5.86\text{Hz}$, 2H).

			3.17 (d, J=9.28Hz, 1H), 2.82 (q, J=6.83 Hz, 2H), 2.10-1.95 (m, 1H), 1.40 (t, J=7.32Hz, 3H), 1.22 (t, J=6.83Hz, 3H), 1.14 (d, J=6.34 Hz, 3H), 0.99 (d, J=6.34Hz, 3H).
18		Liquid, 56%	8.00-7.90 (m, 2H), 7.50-7.40 (m, 3H), 7.29 (d, J=8.79Hz, 2H), 6.81 (s, 1H), 6.57 (d, J=8.79Hz, 2H), 4.33 (t, J=5.86Hz, 2H), 4.11 (q, J=6.84Hz, 2H), 3.54 (t, J=5.86Hz, 2H), 3.32 (t, J=7.83Hz, 1H), 2.82 (q, J=7.32 Hz, 2H), 1.90-1.50 (m, 2H), 1.40 (t, J=7.32Hz, 3H), 1.40 (t, J=7.32Hz, 3H), 0.98 (t, J=7.33Hz, 3H).
19		Liquid, 69%	8.10-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.38 (d, J=8.79Hz, 2H), 6.78 (d, J=8.79Hz, 2H), 6.79 (s, 1H), 4.48 (t, J=4.88Hz, 2H), 4.31 (t, J=4.88Hz, 2H), 4.08 (q, J=7.32Hz, 2H), 3.23 (d, J=8.79Hz, 1H), 3.08 (q, J=7.33 Hz, 2H), 2.15-1.95 (m, 1H), 1.46 (t, J=7.33 Hz, 3H), 1.26 (t, J=7.32Hz, 3H), 1.13 (d, J=6.84Hz, 3H), 0.99 (d, J=6.84Hz, 3H).
20		Liquid, 65%	8.05-8.00 (m, 2H), 7.50-7.40 (m, 3H), 7.30 (d, J=8.32Hz, 2H), 6.81 (s, 1H), 6.57 (d, J=8.32Hz, 2H), 4.57 (bs, 1H, D2O exchangeable), 4.33 (t, J=7.33Hz, 2H), 4.10 (q, J=7.32Hz, 2H), 3.56-3.53 (m, 3H), 2.82 (q, J=7.00 Hz, 2H), 1.75-1.52 (m, 3H), 1.40 (t, J=7.00 Hz, 3H), 1.29-0.88 (m, 9H).

21		Liquid, 80%	7.98-7.93 (m, 2H), 7.45-7.26 (m, 5H), 6.83 (d, J=8.79 Hz, 2H), 6.67 (s, 1H), 4.49 (s, 2H), 4.31-4.13 (m, 4H), 3.19 (t, J=7.32 Hz, 2H), 2.69 (q, J=7.83 Hz, 2H), 1.36-1.21 (m, 6H),
----	---	----------------	--

Example 22

Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}propanoate



5

To a solution of 1-[2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl]-2-(aminophenoxy)ethane (1.9 g, 5.67 mmol) (Ref. US 6,310,069) in dry DMF (20 mL) was added K₂CO₃ and stirred at RT for 30 min. To this ethyl-2-bromopropanoate (1.54 g, 8.51 mmol), was added and the mixture was stirred at 50 °C for 14 h. The

10 reaction mixture was filtered, washed with EtOAc and the combined filtrates were washed with water and extracted with EtOAc. The organic layer was dried over Na₂SO₄, evaporated the solvent and the crude compound was purified by column chromatography by eluting with 25% EtOAc : pet. ether to give the title compound as a brownish low melting solid (mp : 40 °C, 1.867 g, 76%).

15

¹H NMR (CDCl₃, 200MHz): δ 8.03 (m, 2H), 7.98-7.26 (m, 3H), 6.78 (s, 1H), 6.70 (d, J=8.79Hz, 2H), 6.54 (d, J=8.79Hz, 2H), 4.42 (t, J=4.88Hz, 2H), 4.23 (t, J=4.88Hz, 2H), 4.14 (q, J=7.33Hz, 2H), 4.02 (q, J=6.84Hz, 1H), 3.08 (q, J=7.33Hz, 2H), 1.50-1.29 (m, 6H), 1.22 (t, J=7.33Hz, 3H).

20

The compounds given in Table VII were also prepared using a similar method described in Example 22.


TABLE VII

Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
23		Gummy oil, 50%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 6.78 (s, 1H), 6.69 (d, J=9.28Hz, 2H), 6.61 (d, J=9.28Hz, 2H), 4.44 (t, J=4.88 Hz, 2H), 4.24 (t, J=4.88Hz, 2H), 4.13 (q, J=7.33Hz, 2H), 3.08 (q, J=7.33Hz, 2H), 1.47 (s, 6H), 1.40-1.10 (m, 6H).
24		40 °C, 65%	8.10-7.95 (m, 2H), 7.50-7.40 (m, 3H), 6.79 (s, 1H), 6.71 (d, J=8.79Hz, 2H), 6.55 (d, J=8.79Hz, 2H), 4.45 (t, J=4.88 Hz, 2H), 4.24 (t, J=4.88Hz, 2H), 4.14 (q, J=7.33Hz, 2H), 3.95 (t, J=6.84Hz, 1H), 3.09 (q, J=7.32 Hz, 2H), 2.40-2.20 (m, 2H), 1.80-1.60 (m, 2H), 1.43 (t, J= 7.32Hz, 3H), 1.27 (t, J=7.33Hz, 3H), 0.95 (t, J=7.33Hz, 3H).
25		88-89 °C, 56%	8.10-8.00 (m, 2H), 7.50-7.40 (m, 3H), 6.79 (s, 1H), 6.71 (d, J=9.28Hz, 2H), 6.54 (d, J=9.28Hz, 2H), 4.47 (t, J=4.89 Hz, 2H), 4.23 (t, J=4.89Hz, 2H), 4.07 (q, J=6.84Hz, 2H), 4.00 (t, J=7.60Hz, 2H), 3.90 (q, J=6.84Hz, 1H), 3.09 (q, J=7.32Hz, 2H), 1.70-1.50 (m, 5H), 1.41 (t, J=7.32 Hz, 3H), 1.35-1.20 (m, 11H), 0.88 (t, J=5.86Hz, 3H).

Example 26

2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-3-methyl butanoic acid

5







- To ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-3-methyl butanoate (obtained from Example 1) (1.8 g, 3.0 mmol) in THF : MeOH (1:3) mixture (10 mL) was added
- 5 LiOH (1.8 g, 4.28 mmol) dissolved in water (4 mL). The reaction mixture was stirred at RT for 12 h and the solvent was evaporated, diluted with water (10 mL) and acidified the mixture with 2 N HCl to pH 4 and extracted with EtOAc and washed with water, brine and dried over Na₂SO₄ and evaporated the solvent. The resulting
- 10 crude material was purified over silica gel column by eluting with 1% MeOH : CHCl₃ to obtain the title compound as fluffy white solid (1.5 g, 89%).
- ¹H NMR (CDCl₃, 200MHz): δ 8.10-7.90 (m, 2H), 7.59 (d, J=7.81Hz, 2H), 7.50-7.39 (m, 3H), 7.32 (d, J=7.81Hz, 2H), 6.79 (s, 1H), 4.45 (s, 2H), 3.67 (t, J=7.32Hz, 2H), 3.55 (d, J=8.79Hz, 1H), 2.67 (q, J=7.33Hz, 2H), 2.30-2.15 (m, 1H), 1.60-1.45 (m, 2H), 1.40-1.05 (m, 17H), 0.84 (t, J=6.84Hz, 3H).
- 15 The compounds given in Table VIII were also prepared using a similar method described in Example 26.






TABLE VIII


Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
27		210 °C, 65%	8.10-7.95 (m, 2H), 7.68 (d, J=8.30Hz, 2H), 7.55-7.40 (m, 3H), 6.88 (d, J=8.30 Hz, 2H), 6.86 (s, 1H), 4.39 (t, J=4.32 Hz, 2H), 3.80 (t, J= 4.32Hz, 2H), 3.00 (q, J=6.84Hz, 2H), 1.70 (s, 6H), 1.47 (t, J=6.84Hz, 3H).
28		132-134 °C, 43%	8.10-7.95 (m, 2H), 7.55-7.40 (m, 3H), 7.32 (d, J=8.30Hz, 2H), 6.91 (d, J=8.30 Hz, 2H), 6.80 (s, 1H), 4.38 (t, J=4.34 Hz, 2H), 3.73 (t, J= 4.34Hz, 2H), 3.28 (t, J= 6.83Hz, 2H), 3.08 (q, J=7.82Hz, 2H), 1.95-

Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
			1.80 (m, 10H), 1.63 (s, 6H), 1.44 (t, J=7.82Hz, 3H), 0.84 (t, J=4.83 Hz, 3H).
29		120 °C, 71%	8.10-8.00 (m, 2H), 7.55-7.45 (m, 3H), 7.38 (d, J=7.09Hz, 2H), 6.86 (d, J=7.09 Hz, 2H), 6.83 (s, 1H), 4.91 (s, 2H), 3.06 (q, J=7.32Hz, 2H), 1.56 (s, 6H), 1.45 (t, J=7.32Hz, 3H).
30		68-70 °C, 93%	8.05-8.00 (m, 2H), 7.55-7.45 (m, 3H), 7.28 (d, J=8.31Hz, 2H), 7.02 (d, J=8.31 Hz, 2H), 6.78 (s, 1H), 4.50 (s, 2H), 3.66 (t, J= 7.33Hz, 2H), 2.70 (q, J= 7.32Hz, 2H), 2.25-2.00 (m, 2H), 1.67 (s, 6H), 1.38 (t, J= 7.32Hz, 3H), 1.38-1.18 (m, 8H), 0.85 (t, J=6.83 Hz, 3H).
31		158 – 160 °C, 79%	8.10-7.95 (m, 2H), 7.50-7.40 (m, 3H), 6.89 (d, J=8.79Hz, 2H), 6.81 (s, 1H), 6.76 (d, J=8.79 Hz, 2H), 4.48 (t, J=4.89 Hz, 2H), 4.48 (t, J= 4.89Hz, 2H), 3.09 (q, J=7.32Hz, 2H), 1.50 (s, 6H), 1.45 (t, J=7.32Hz, 3H).
32		190-192 °C, 64%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 6.82 (d, J=8.79Hz, 2H), 6.74 (d, J=8.79 Hz, 2H), 6.73 (s, 1H), 4.60-4.50 (m, 3H), 4.24 (t, J= 4.40 Hz, 2H), 3.09 (q, J= 7.33Hz, 2H), 2.00-1.90 (m, 2H), 1.60- 1.40 (m, 5H), 0.95 (t, J=6.83Hz, 3H).
33		159 – 161 °C, 71%	8.10-8.05 (m, 2H), 7.50-7.40 (m, 3H), 6.88 (d, J=8.79Hz, 2H), 6.79 (s, 1H), 6.78 (d, J=8.79 Hz, 2H), 4.47 (t, J=4.89 Hz, 2H), 4.28 (t, J= 4.89Hz, 2H), 3.08 (q, J=6.84Hz, 2H), 1.88 (q, J=7.33Hz, 2H), 1.44 (t, J=6.84 Hz, 3H), 1.36 (s, 3H), 1.01 (t, J=7.33Hz, 3H)..

Exam N .	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
34		52°C, 20%	8.10-7.90 (m, 2H), 7.66 (d, J=7.81Hz, 2H), 7.50-7.40 (m, 3H), 7.36 (d, J=7.81 Hz, 2H), 6.77 (s, 1H), 4.47 (s, 2H), 3.70 (t, J= 7.32Hz, 2H), 2.70 (q, J= 7.32Hz, 2H), 1.60-1.40 (m, 2H), 1.55 (s, 6H), 1.37 (t, J= 7.32Hz, 3H), 1.30-1.10 (m, 8H), 0.84 (t, J=4.99 Hz, 3H)
35		192 -194 °C, 66%	8.20-8.00 (m, 2H), 7.50-7.40 (m, 3H), 6.89 (s, 1H), 6.70 (d, J=8.79Hz, 2H), 6.48 (d, J=8.79 Hz, 2H), 4.35 (t, J=4.82 Hz, 2H), 4.12 (t, J= 4.82Hz, 2H), 3.84 (q, J=6.84Hz, 1H), 3.04 (q, J=7.33Hz, 2H), 1.36 (t, J=7.33 Hz, 3H), 1.31 (d, J=6.84Hz, 3H)..
36		52-54 °C, 54%	8.00-7.90 (m, 2H), 7.55-7.40 (m, 3H), 7.26 (d, J=7.81Hz, 2H), 7.03 (d, J=7.81 Hz, 2H), 6.72 (s, 1H), 4.51 (s, 2H), 3.67 (t, J= 4.52Hz, 2H), 2.81 (q, J= 5.87Hz, 2H), 2.60-2.30 (m, 2H), 2.04 (t, J=7.33Hz, 2H), 1.58 (s, 3H), 1.41 (t, J= 5.87Hz, 3H), 1.35-1.18 (m, 8H), 1.05 (t, 7.33Hz, 3H) , 0.85 (t, J=7.22 Hz, 3H).
37		48-50 °C, 74%	8.00-7.90 (m, 2H), 7.50-7.39 (m, 3H), 7.30 (d, J=8.79Hz, 2H), 7.02 (d, J=8.79 Hz, 2H), 6.85 (s, 1H), 4.67 (t, J= 5.86 Hz, 1H), 4.40 (s, 2H), 3.75-3.55 (m, 2H), 2.67 (q, J= 7.33Hz, 2H), 2.10-1.90 (m, 2H), 1.70 -1.40 (m, 2H), 1.34 (t, J= 7.33Hz, 3H), 1.25-1.10 (m, 10H), 1.00 (t, J=7.33Hz, 3H), 0.85 (t, J=6.84 Hz, 3H).
38		168 - 169 °C, 74%	8.03-7.45 (m, 2H), 7.55-7.40 (m, 3H), 7.23 (d, J=9.78Hz, 2H), 6.89 (s, 1H), 6.77 (d, J=9.78 Hz, 2H), 4.44 (t, J=4.88 Hz, 2H), 4.27 (t, J= 4.88Hz,


Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
			2H), 3.04 (q, J=7.33Hz, 2H), 2.99 (s, 6H), 1.44 (t, J=7.33Hz, 3H).
39		155 – 157 °C, 43%	8.05-7.95 (m, 2H), 7.55-7.40 (m, 3H), 6.79 (s, 1H), 6.72 (d, J=8.79Hz, 2H), 6.60 (d, J=8.79 Hz, 2H), 4.44 (t, J=4.88 Hz, 2H), 4.23 (t, J= 4.88 Hz, 2H), 3.89 (t, J=5.86Hz, 1H), 3.08 (q, J=7.32Hz, 2H), 1.90- 1.60 (m, 2H), 1.55- 1.25 (m, 5H), 0.93 (t, J=7.33 Hz, 3H).
40		Gummy oil, 40%	8.05-7.95 (m, 2H), 7.59 (d, J=8.30Hz, 2H) 7.50-7.40 (m, 3H), 7.32 (d, J=8.30 Hz, 2H), 6.79 (s, 1H), 4.45 (s, 2H), 3.75 (t, J= 7.33 Hz, 1H), 3.67 (t, J=7.33Hz, 2H), 2.67 (q, J=7.33Hz, 2H), 2.10-1.70 (m, 2H), 1.60 –1.42 (m, 2H), 1.34 (t, J= 7.33 Hz, 3H), 1.30-1.05 (m, 10H), 0.96 (t, J=7.33Hz, 3H), 0.83 (t, J=6.34 Hz, 3H).
41		164 – 166 °C, 68%	8.02-7.97 (m, 2H), 7.46-7.43 (m, 3H), 7.35 (d, J=8.79 Hz, 2H), 6.81 (d, J=8.79 Hz, 2H), 6.63 (s, 1H), 4.86 (s, 2H), 4.25 (t, J=7.08 Hz, 2H), 3.24 (t, J=7.32 Hz, 2H), 2.69 (q, J=7.32 Hz, 2H), 1.30 (t, J=7.08 Hz, 3H),
42		Liquid, 70%	8.05-7.90 (m, 2H), 7.60 (d, J=8.30Hz, 2H) 7.50-7.40 (m, 3H), 7.33 (d, J=8.30 Hz, 2H), 6.80 (s, 1H), 4.46 (s, 2H), 3.68 (t, J=7.33 Hz, 2H), 3.67 (t, J=7.32 Hz, 1H), 2.68 (q, J=7.33Hz, 2H), 2.10-1.80 (m, 2H), 1.55 –1.40 (m, 2H), 1.36 (t, J= 7.33 Hz, 3H), 1.30-1.05 (m, 8H), 1.10 (t, J=7.33Hz, 3H), 0.85 (t, J=6.35 Hz, 3H).

Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
43		58-60 °C, 65%	8.05-7.95 (m, 2H), 7.60 (d, J=8.30Hz, 2H) 7.50-7.40 (m, 3H), 7.34 (d, J=8.30 Hz, 2H), 6.77 (s, 1H), 4.46 (s, 2H), 3.83 (t, J= 8.30 Hz, 1H), 3.70 (t, J=7.33 Hz, 2H), 2.69 (q, J= 7.32Hz, 2H), 2.20-2.00 (m, 2H), 1.95 -1.80 (m, 1H), 1.60-1.40 (m, 2H), 1.36 (t, J= 7.33 Hz, 3H), 1.30-1.10 (m, 11H), 1.00-0.80(m, 6H).
44		64 °C, 82%	8.10-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.39 (d, J=8.30Hz, 2H), 6.79 (s, 1H), 6.77 (d, J=8.30 Hz, 2H), 4.45 (t, J= 4.88 Hz, 2H), 4.28 (t, J=4.88Hz, 2H), 3.24 (d, J=8.79Hz, 1H), 3.05 (q, J= 7.32Hz, 2H), 2.10- 1.90 (m, 1H), 1.43 (t, J=7.32Hz, 3H), 1.13 (d, J=6.35Hz, 3H), 1.03 (d, J=6.35 Hz, 3H).
45		195 - 200 °C, 43%	8.15-8.00 (m, 2H), 7.60-7.40 (m, 3H), 7.36 (d, J=7.39Hz, 2H), 6.86 (s, 1H) 6.66 (d, J=7.39 Hz, 2H), 5.00 (s, 2H), 3.25 (d, J=7.32Hz, 1H), 2.89 (q, J=7.32 Hz, 2H), 2.05-1.95 (m, 1H), 1.42 (t, J= 7.32Hz, 3H), 1.10-1.00 (m, 6H).
46		118 °C, 68%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.12 (d, J=8.79Hz, 2H), 6.81 (s, 1H), 6.56 (d, J=8.79 Hz, 2H), 4.31 (t, J= 5.86 Hz, 2H), 3.52 (t, J= 5.86Hz, 2H), 3.34 (t, J=7.33Hz, 1H), 2.80 (q, J= 7.33Hz, 2H), 1.90- 1.60 (m, 2H), 1.38 (t, J=7.33 Hz, 3H), 1.03 (t, J= 7.33Hz, 3H).
47		62-64 °C, 95%	8.05-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.33 (d, J=8.30Hz, 2H), 6.82 (s, 1H), 6.58 (d, J=8.30Hz, 2H), 4.32 (t, J=5.40 Hz, 2H), 3.53-3.40 (m, 3H),

Exam No.	Structure	Mp, Yield, Nature	¹ H NMR (CDCl ₃): δ
			2.81 (q, J= 7.30Hz, 2H), 1.84-1.51 (m, 3H), 1.36 (t, J=7.30 Hz, 3H), 0.95-0.80 (m, 6H).
48		65-70 °C, 55%	8.00-7.95 (m, 2H), 7.50-7.40 (m, 3H), 7.32 (d, J=8.31Hz, 2H), 6.81 (s, 1H), 6.54 (d, J=8.31 Hz, 2H), 4.62 (bs, 1H, D ₂ O exchangeable), 4.29 (t, J=5.86 Hz, 2H), 3.49 (t, J=5.86 Hz, 2H), 3.17 (d, J=9.27Hz, 1H), 2.79 (q, J=7.32Hz, 2H), 2.15- 1.95 (m, 1H), 1.37 (t, J=7.32 Hz, 3H), 1.16 (d, J=6.83Hz, 3H), 1.04 (d, J=6.83 Hz, 3H).

Example 49

2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoic acid, arginine salt




To 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoic acid, (obtained from example 42) (130 mg, 0.236 mmol) in dry methanol (5 mL) was added L-arginine (41 mg, 0.236 mmol) and stirred at 30 °C for 24 h. The solvent was evaporated and the residue was triturated with dry ethyl ether and dried under vacuum at 50 °C to give the title compound as a white amorphous solid (mp : 104-6 °C, yield 90%).

IR(KBr): ν cm⁻¹ 3358, 2929, 1667, 1584.

Example 50

2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-4-methylpentanoic acid, arginine salt

64




The title compound is prepared from 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenylsulfanyl]-2-methylpentanoic acid, according to the similar method to that described in Example 48 (mp : 120-122 °C; yield 90%)

IR(KBr): ν cm⁻¹ 3356, 3162, 1664.

Example 51

2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoic acid, magnesium salt



10

To 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]butanoic acid (obtained from example 42) (150 mg, 0.284 mmol) in dry methanol (5 mL) was added magnesium hydroxide (8.28 mg, 0.142 mmol) and refluxed for 24 h. The solvent was evaporated and the residue was triturated with dry ethyl ether and dried under vacuum at 50 °C to give the title compound as a white amorphous solid (mp : 138-142 °C, yield 90%).


15

IR(KBr): ν cm⁻¹ 3421, 2927, 1670, 1546.

The compounds given in Table IX were also prepared using a similar method described in Example 51.

20 **TABLE IX**

Exam No.	Structure	Mp, Yield, Nature	IR
52		140-144 °C, 90%	3441, 2920, 1671.

53		140-142 °C, 92%	3446, 2937, 1670.
----	---	-----------------	-------------------

The compounds of the present invention lower random blood sugar level, triglyceride, total cholesterol, LDL, VLDL and increased HDL. This was demonstrated by *in vitro* as well as *in vivo* animal experiments.

5 Demonstration of Efficacy of Compounds:

A) In vitro:

a) Determination of hPPAR α activity :

Ligand binding domain of hPPAR α was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector. Using superfect (Qiagen, Germany) as transfecting reagent HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter. Compound was added at different concentrations after 42 hrs of transfection and incubated overnight. Luciferase activity as a function of compound binding/activation capacity of PPAR α was measured using Packard Luclite kit (Packard, USA) in Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene. 1992. 118 : 137 -141; Superfect Transfection Reagent Handbook. February 1997. Qiagen, Germany).

b) Determination of hPPAR γ activity:

Ligand binding domain of hPPAR γ 1 was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector. Using lipofectamine (Gibco BRL, USA) as transfecting reagent HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter. Compound was added at 1 μ M concentration after 48 hrs of transfection and incubated overnight. Luciferase activity as a function of drug binding/activation capacity of PPAR γ 1 was measured using Packard Luclite kit (Packard, USA) in Packard Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene. 1992. 118 : 137 -141; Guide to Eukaryotic Transfections with Cationic Lipid Reagents. Life Technologies, GIBCO BRL, USA).

Example No	Concentration	PPAR α	Concentration	PPAR γ
Example 35	50 μ M	6.2	1 μ M	2.2
Example 36	50 μ M	7.5	1 μ M	1.2
Example 43	50 μ M	6.7	1 μ M	2.2
Example 45	50 μ M	7.2	1 μ M	0.8
Example 46	50 μ M	6.5	1 μ M	3.1
Wy 14643*	50 μ M	7	1 μ M	-
Rosiglitazone	50 μ M	-	1 μ M	18

*reference standard

c) **Determination of HMG CoA reductase inhibition activity:**

Liver microsome bound reductase was prepared from 2% cholestyramine fed rats at mid-dark cycle. Spectrophotometric assays were carried out in 100 mM KH₂PO₄, 4 mM DTT, 0.2 mM NADPH, 0.3 mM HMG CoA and 125 μ g of liver microsomal enzyme. Total reaction mixture volume was kept as 1 ml. Reaction was started by addition of HMG CoA. Reaction mixture was incubated at 37 °C for 30 min and decrease in absorbance at 340 nm was recorded. Reaction mixture without substrate was used as blank (Goldstein, J. L and Brown, M. S. Progress in understanding the LDL receptor and HMG CoA reductase, two membrane proteins that regulate the plasma cholesterol. J. Lipid Res. 1984, 25: 1450 – 1461). The test compounds inhibited the HMG CoA reductase enzyme.

B) In vivo

Efficacy in genetic models:

Mutation in colonies of laboratory animals and different sensitivities to dietary regimens have made the development of animal models with non-insulin dependent diabetes and hyperlipidemia associated with obesity and insulin resistance possible. Genetic models such as db/db and ob/ob (Diabetes, (1982) 31(1) : 1- 6) mice and zucker fa/fa rats have been developed by the various laboratories for understanding the pathophysiology of disease and testing the efficacy of new antidiabetic compounds (Diabetes, (1983) 32: 830-838 ; Annu. Rep. Sankyo Res. Lab. (1994). 46 : 1-57). The homozygous animals, C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese, hyperglycemic, hyperinsulinemic

and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous are lean and normoglycemic. In db/db model, mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled. The state of pancreas and its course vary according to the models. Since this model resembles that of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.

Male C57BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used in the experiment. The mice were provided with standard feed (National Institute of Nutrition (NIN), Hyderabad, India) and acidified water, ad libitum. The animals having more than 350 mg / dl blood sugar were used for testing. The number of animals in each group was 4.

Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 0.001 mg to 30 mg / kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml / kg). On 6th day the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.

The random blood sugar and triglyceride levels were measured by collecting blood (100 µl) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma. The plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO₄ oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, Hyderabad, India) methods respectively.

The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula.

No adverse effects were observed for any of the mentioned compounds of invention in the above test.

Compound	Dose (mg / kg)	Reduction in Blood Glucose Level (%)	Triglyceride Lowering (%)
Example 30	10	34	63
Example 26	10	41	45
Example 43	10	39	43

The ob/ob mice are obtained at 5 weeks of age from Bomholtgard, Denmark and were used at 8 weeks of age. Zucker fa/fa fatty rats are obtained from IffaCredo, France at 10 weeks of age and were used at 13 weeks of age. The animals are maintained under 12 hour light and dark cycle at 25 ± 1 °C. Animals are given standard laboratory chow (NIN, Hyderabad, India) and water, *ad libitum* (Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I and Horikoshi, H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988. 37 : 1549 – 1558).

The test compounds are to be administered at 0.1 to 30 mg/kg/day dose for 9 days. The control animals received the vehicle (0.25 % carboxymethylcellulose, dose 10 ml/kg) through oral gavage.

The blood is to be collected in fed state 1 hour after drug administration on 0 and 9 day of treatment. The blood is collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample is separated for triglyceride, glucose, free fatty acid, total cholesterol and insulin estimations. Measurement of plasma triglyceride, glucose, total cholesterol will be done using commercial kits (Dr. Reddy's Laboratory, Diagnostic Division kits, Hyderabad, India). The plasma free fatty acid will be measured using a commercial kit form Boehringer Mannheim, Germany. The plasma insulin will be measured using a RIA kit (BARC, India). The reduction of various parameters examined are calculated according to the formula given below.

In ob/ob mice oral glucose tolerance test is performed after 9 days treatment. Mice are fasted for 5 hrs and challenged with 3 gm/kg of glucose orally. The blood

samples are collected at 0, 15, 30, 60 and 120 min for estimation of plasma glucose levels.

The experimental results suggest that the compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for diabetes, obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.

Blood glucose level and triglycerides are also lowered at doses greater than 10 mg/kg. Normally, the quantum of reduction is dose dependent and plateaus at certain dose.

b) Cholesterol lowering activity in hypercholesterolemic rat models:

Male Sprague Dawley rats (NIN stock) are bred in DRF animal house. Animals are maintained under 12 hour light and dark cycle at 25 ± 1 °C. Rats of 180 - 200 gram body weight range are used for the experiment. Animals are made hypercholesterolemic by feeding 2% cholesterol and 1% sodium cholate mixed with standard laboratory chow [National Institute of Nutrition (NIN), Hyderabad, India] for 6 days. Throughout the experimental period the animals were maintained on the same diet (Petit, D., Bonnefis, M. T., Rey, C and Infante, R. Effects of ciprofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis. 1988. 74 : 215 – 225).

The test compounds are administered orally at a dose 0.1 to 30 mg/kg/day for 3 days. Control group is treated with vehicle alone (0.25 % Carboxymethylcellulose; dose 10 ml/kg).

The blood samples are collected in fed state 1 hour after drug administration on 0 and 3 day of compound treatment. The blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample is separated for total cholesterol, HDL and triglyceride estimations. Measurement of plasma triglyceride, total cholesterol and HDL is done using commercial kits (Dr. Reddy's Laboratory, Diagnostic Division, India). LDL and VLDL cholesterol is calculated from the data obtained for total cholesterol, HDL and triglyceride. The reduction of various parameters examined is calculated according to the formula given below.

c) Plasma triglyceride and total cholesterol lowering activity in Swiss albino mice and Guinea pigs:

Male Swiss albino mice (SAM) and male Guinea pigs were obtained from NIN and housed in DRF animal house. All these animals were maintained under 12 hour light and dark cycle at $25 \pm 1^{\circ}\text{C}$. Animals were given standard laboratory chow (NIN, Hyderabad, India) and water, *ad libitum*. SAM of 20 - 25 g body weight range and Guinea pigs of 500 - 700 g body weight range were used (Oliver, P., Plancke, M. O., Marzin, D., Clavey, V., Sauzies, J and Fruchart, J. C. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. *Atherosclerosis*, 1988. 70 : 107 - 114).

The test compounds were administered orally to Swiss albino mice at 0.3 to 30 mg/kg/day dose for 6 days. Control mice were treated with vehicle (0.25% Carboxymethylcellulose; dose 10 ml/kg). The test compounds were administered orally to Guinea pigs at 0.3 to 30 mg/kg/day dose for 6 days. Control animals were treated with vehicle (0.25% Carboxymethylcellulose; dose 5 ml/kg).

The blood samples were collected in fed state 1 hour after drug administration on 0 and 6 day of treatment. The blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride and total cholesterol (Wieland, O. *Methods of Enzymatic analysis*. Bergermeyer, H. O., Ed., 1963. 211 - 214; Trinder, P. *Ann. Clin. Biochem.* 1969. 6 : 24 - 27). Measurement of plasma triglyceride, total cholesterol and HDL were done using commercial kits (Dr. Reddy's Diagnostic Division, Hyderabad, India).

Compound	Dose (mg / kg)	Triglyceride Lowering (%)
Example 44	3	36
Example 43	3	44
Example 49	10	69

Formulae for calculation:

1. Percent reduction in Blood sugar / triglycerides / total cholesterol were calculated according to the

$$\text{Percent reduction (\%)} = \left[1 - \frac{TT / OT}{TC / OC} \right] \times 100$$

formula:

5 OC = Zero day control group value

OT = Zero day treated group value

TC = Test day control group value

TT = Test day treated group value


2. LDL and VLDL cholesterol levels were calculated according to the formula :

10 LDL cholesterol in mg/dl = [Total cholesterol - HDL cholesterol - $\frac{\text{Triglyceride}}{5}$] mg/dl

VLDL cholesterol in mg/dl = [Total cholesterol - HDL cholesterol - LDL cholesterol] mg/dl.

CLAIMS

1. A compound of formula (I)



- its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R^1 , R^2 and the group R^3 when attached to the carbon atom, are the same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R^3 when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; the linking group represented by $-(\text{CH}_2)_m\text{---W---}(\text{CH}_2)_n\text{---}$ is attached either through nitrogen atom or through carbon atom; W represents O, S, NR^7 , C(=O) , ---O---C(=O) , C(=O)---O , C(=O)---NR^7 , $\text{---O---C(=O)---NR}^7$, $\text{NR}^7\text{---}(\text{CH}_2)_n\text{C(=O)---NR}^7$, $\text{NR}^7\text{---C(=O)---O}$, $\text{NR}^7\text{---C(=O)---NR}^7$, $\text{NR}^7\text{---C(=O)}$, $\text{SO}_2\text{---NR}^7$, $\text{NR}^7\text{---SO}_2$, where R^7 represents hydrogen, $(\text{C}_1\text{---C}_{12})$ alkyl, aryl, or aralkyl group; m and n are integers ranging from 0-4; Ar represents substituted or unsubstituted divalent single or fused aromatic or heterocyclic group; R^4 and R^5 are the same or different and represent hydrogen,

hydroxy, alkoxy, halogen or substituted or unsubstituted groups selected from (C₁-C₁₂) alkyl, aralkyl or heteroaralkyl groups; R⁶ is hydrogen or a substituted or unsubstituted group selected from (C₁-C₁₂) alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents oxygen or NR⁸, where

5 R⁸ represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; R⁶ and R⁸ together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, one or two nitrogen atoms and may optionally contain one or more heteroatoms selected from oxygen or sulfur; Q represents O, S, SO, SO₂ or

10 NR⁹ wherein R⁹ represents hydrogen, or substituted, or unsubstituted group selected from (C₁-C₁₂)alkyl, cycloalkyl, aryl, hydroxyalkyl, aralkylheterocyclyl, heteroaryl, or heteroaralkyl groups; p is an integer of 0 or 1.


2. A compound according to claim 1, wherein when the groups represented by R¹, R² and the group R³ when attached to carbon atom are substituted, the

15 substituents are selected from halogen, hydroxy, nitro, thio or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, alkoxycarbonyl, monoalkylamino, dialkylamino, alkylthio groups,

20 carboxylic acid or its derivatives or sulfonic acid or its derivatives.

3. A compound according to claim 1, wherein Ar represents unsubstituted or substituted divalent phenylene, naphthylene, pyridyl, quinoliny, benzofuryl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl, indolyl, indoliny, azaindolyl, azaindoliny, pyrazolyl, benzothiazolyl or benzoxazolyl group.

25 4. A process for the preparation of compound of formula (I)




its derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, wherein X represents O or S; the groups R¹, R² and the group R³ when attached to

the carbon atom, are the same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxy carbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxy carbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R^3 when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, acylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy, alkoxycarbonyl, aryloxy carbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; the linking group represented by $-(CH_2)_m-W-(CH_2)_n-$ is attached either through nitrogen atom or through carbon atom; W represents O, S, NR^7 , $-C(=O)$, $-O-C(=O)$, $C(=O)-O$, $C(=O)-NR^7$, $-O-C(=O)-NR^7$, $NR^7-(CH_2)_nC(=O)-NR^7$, $NR^7-C(=O)-O-$, $NR^7-C(=O)-NR^7$, $NR^7-C(=O)$, SO_2-NR^7 , NR^7-SO_2 , where R^7 represents hydrogen, (C_1-C_{12}) alkyl, aryl, aralkyl group; m and n are integers ranging from 0-4; Ar represents substituted or unsubstituted divalent single or fused aromatic or heterocyclic group; R^4 and R^5 are the same or different and represent hydrogen, hydroxy, alkoxy, halogen or substituted or unsubstituted groups selected from (C_1-C_{12}) alkyl, aralkyl or heteroaralkyl groups; R^6 is hydrogen or a substituted or unsubstituted group selected from (C_1-C_{12}) alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents oxygen or NR^8 , where R^8 represents hydrogen or substituted or unsubstituted group selected from alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; R^6 and R^8 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, one or two nitrogen atoms and may optionally contain one or more heteroatoms selected from oxygen, or sulfur; Q represents O, S, SO, SO_2 or


NR⁹ wherein R⁹ represents hydrogen, substituted or unsubstituted groups selected from (C₁-C₁₂)alkyl, cycloalkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl; and p is an integer of 0 or 1, which comprises,

(a) reacting the compound of formula (IIIa)




5

where A and R¹, R², R³ and X are as defined above with a compound of formula (IIIb)




where L¹ is a leaving group and all other symbols are as defined in claim 1 or

10 (b) reacting a compound of formula (IIIc)




where L² represents a halogen atom, W represents C=O and all other symbols are as defined above with a compound of formula (IIId)




15 where all symbols are as defined above or

(c) reacting a compound of formula (IIIe)




where L¹ is a leaving group and all other symbols are as defined above with a compound of formula (IIIf)




where all symbols are as defined above or

(d) reacting the compound of formula (IIIg)



5 where L^3 is a leaving group or L^3 represents COOH , or COCl , with compound of formula (IIIh)



where W represents NR^7 and all symbols are as defined above to produce a compound of formula (I) where W represents NR^7 and all other symbols are as defined above.

5. A compound according to claim 1 which is selected from:

(±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate ;

(+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate ;

(-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoate ;

(±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;

(+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;

(-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;

(±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl) carbamoyl]phenoxy}-2-methyl propanoate;

25 ethylcarbamoyl]phenoxy}-2-methyl propanoate;

- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl) ethylcarbamoyl]phenoxy}-2-methyl propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl) ethylcarbamoyl]phenoxy}-2-methyl propanoate;
- 5 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]-2-methyl propanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]-2-methyl propanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]-2-methyl propanoate;
- 10 (±) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- (+) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- 15 (-) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl propanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- 20 (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- 25 (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido) phenoxy]-2-methyl butanoate;
- (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate;
- 30 (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-

- ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate;
(-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoate ;
(±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]octanoate;
5 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]octanoate;
(-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenoxy]octanoate;
10 (±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoate;
(+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoate;
(-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoate;
15 (±) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
(+) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
20 (-) Ethyl 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoate;
(±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy}pentanoate;
(+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy}pentanoate;
25 (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy}pentanoate;
(±) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoate;
30 (+) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoate;

- (-) Ethyl 2-[4-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methylcarboxamido]phenyl sulfanyl}-3-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl propanoate;
- 5 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl propanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl propanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl butanoate;
- 10 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl butanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}-2-methyl butanoate;
- 15 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoate;
- (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoate;
- 20 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino] phenylsulfanyl}-3-methyl butanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino] phenylsulfanyl}-3-methyl butanoate;
- 25 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl amino] phenylsulfanyl}-3-methyl butanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl}butanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl}butanoate;
- 30 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-

yl)ethylamino] phenyl sulfanyl} butanoate;

(±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl} butanoate;

5 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl} butanoate;

(-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenyl sulfanyl} butanoate;

(±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} -4-methyl pentanoate;

10 (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} -4-methyl pentanoate;

(-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenyl sulfanyl} -4-methyl pentanoate;

15 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetate;

(+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetate;

(-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetate;

20 (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} propanoate;

(+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} propanoate;

25 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} propanoate;

(±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} -2-methyl propanoate;

(+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} -2-methyl propanoate;

30 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino} -2-methyl propanoate;

- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino}pentanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino}pentanoate;
- 5 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] anilino}pentanoate;
- (±) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] (heptyl) anilino}propanoate;
- (+) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] (heptyl) anilino}propanoate;
- 10 (-) Ethyl 2-{4-[2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] (heptyl) anilino}propanoate;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- 15 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- 20 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- 25 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl)carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl)carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethyl(heptyl)carbamoyl] phenoxy}-2-methyl propanoic acid or its salts;
- 30

(±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid or its salts;

(+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid or its salts;

5 (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid or its salts;

(±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;

10 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;

(-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid or its salts;

(±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid or its salts;

15 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid or its salts;

(-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid or its salts;

20 (±) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoic acid or its salts;

(+) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoic acid or its salts;

(-) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}pentanoic acid or its salts;

25 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;

(+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;

30 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid or its salts;

- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts ;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts;
- 5 (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid or its salts;
- 10 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- 15 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]-2-methyl butanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid or its salts;
- 20 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid or its salts;
- 25 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid or its salts;
- 30

- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid or its salts;
- 5 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- 10 (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]pentanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- 15 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]propanoic acid or its salts;
- 20 (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]propanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]propanoic acid or its salts;
- 25 (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid or its salts;
- 30

- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid or its salts;
- 5 (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid or its salts;
- (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- 10 (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenyl sulfanyl]-3-methyl butanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- 15 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid or its salts;
- (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- 20 (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-4-methyl pentanoic acid or its salts;
- 25 (±) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-3-methyl butanoic acid or its salts;
- (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-3-methyl butanoic acid or its salts; or
- (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino] phenylsulfanyl}-3-methyl butanoic acid or its salts.
- 30

6. A compound according to claim 1 or 5 which is selected from:

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine,
 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 5 methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 10 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 15 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 20 ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-
 ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-3-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,
 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 25 methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 30 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy

- proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-3-methyl butanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-3-methyl butanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,

methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
 5 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
 10 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
 15 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-
 yl)ethylcarbamoyl]phenoxy}-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine,
 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
 20 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
 25 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
 30 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,

nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl]phenoxy}-2-methyl propanoic acid;

5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, 10 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; 15 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, 20 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylcarbamoyl]phenoxy}-2-methyl propanoic acid ;

25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, 30 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,

- dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
- 5 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
- 10 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1yl)ethyl(heptyl)carbamoyl]phenoxy}-2-methyl propanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,
- 15 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
- 20 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
- 25 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
- 30 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or

ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro
pyrimidin-1yl)ethyl(heptyl)carbamoyle]phenoxy}-2-methyl propanoic acid;

- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,
caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
5 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
10 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
15 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
citrate, succinates, palmoates, methanesulphonates, benzoates, salicylates,
20 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-
1yl)ethyl(heptyl)carbamoyle]phenoxy}-2-methyl propanoic acid;

- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,
caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
25 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
30 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,

isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-

- ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
- 5 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
- 10 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
- 15 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido) phenoxy]-2-methyl propanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine,
- 20 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
- 25 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
- 30 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,

alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 5 ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 10 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 15 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 20 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 25 ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 30 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-

- dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl propanoic acid ;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or

- ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid; Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, 5 glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, 10 metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or 15 substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, 20 ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid; Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, 25 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, 30 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy

- proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl propanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenoxy}pentanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,

methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, 5 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; 10 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, 15 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro pyrimidin-1-yl)ethoxy] phenoxy}pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, 20 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, 25 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; 30 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,

nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-

5 dihydropyrimidin-1-yl)ethoxy] phenoxy} pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, 10 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; 15 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, 20 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Eethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1- 25 yl)ethoxy]phenoxy}-2-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, 30 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,

dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy

5 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

10 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy}-2-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,

15 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-

20 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy

25 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

30 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or

ketoglutarates salts of (-) 2-[4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]phenoxy]-2-methyl butanoic acid;

- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoic acid;

- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,

isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
 5 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-
 10 ylmethyl(heptyl)carboxamido)phenyl sulfanyl]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine,
 caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
 methylglucamine, morpholine, piperazine, piperidine, procaine, purines,
 15 theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-
 dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,
 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine;
 20 alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy
 proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted
 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
 25 alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,
 citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or
 ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-
 30 ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates; hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines,

theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutaramates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid;

- 5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 10 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
- 15 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
- 20 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenoxy]-2-methyl butanoic acid;

- 25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 30 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,

- trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 5 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 10 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
- 15 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
- 20 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 25 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 30 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenoxy]methyl pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid ;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid ;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines,

theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino}-2-methyl propanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid;

- 5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, 10 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, 15 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, 20 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid;

- 25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, 30 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,

- trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 5 unnatural amino acids; *D*-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 10 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy]anilino} pentanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; *N,N'*-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, *N*-ethylmorpholine, *N*-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine,
- 15 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, *N,N'*-diphenylethylenediamine, *N,N'*-dibenzylethylenediamine, *N*-benzyl phenylethylamine, choline, choline hydroxide,
- 20 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 25 unnatural amino acids; *D*-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 30 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl)carboxamido]phenylsulfanyl] pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenylsulfanyl] pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates; hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl)carboxamido)phenylsulfanyl] pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines,

theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, 5 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted 10 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or 15 ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, 20 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, 25 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted 30 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylsulfanyl] phenoxy} acetic acid;

- 5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenethylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 10 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
- 15 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
- 20 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (±) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)methyl(heptyl) carboxamido]phenyl sulfanyl]butanoic acid;

- 25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenethylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 30 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,

- trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 5 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 10 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
- 15 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
- 20 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 25 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 30 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethyl(heptyl) carboxamido)phenyl sulfanyl]-4-methyl pentanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines,

theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid;

- 5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 10 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
- 15 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
- 20 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethoxy] phenylsulfanyl}-2-methyl butanoic acid;

- 25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 30 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,

- trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 5 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 10 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenylsulfanyl]-3-methyl butanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
- 15 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
- 20 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 25 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 30 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-[4-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-ylmethylcarboxamido)phenyl sulfanyl]-3-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl}butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines,

theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, 5 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted 10 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or 15 ketoglutarates salts of (-) 2-[4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenyl sulfanyl]butanoic acid ;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, 20 methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, 25 trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted 30 guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates,

citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid;

- 5 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 10 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine,
- 15 isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates,
- 20 nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid;

- 25 Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine,
- 30 diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine,


- trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 5 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 10 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-4-methyl pentanoic acid;
- Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetythylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-
- 15 ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,
- 20 dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;
- 25 unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates,
- 30 hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (\pm) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid;

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (+) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid; or

Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine; alkylphenylamine, glycinol, phenyl glycinol; glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine;

unnatural amino acids; D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl; ammonium or substituted ammonium salts and aluminum salts; sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, or ketoglutarates salts of (-) 2-{4-[2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl)ethylamino]phenylsulfanyl}-3-methyl butanoic acid.

7. A pharmaceutical composition which comprises a compound of formula (I)



as defined in claims 1 and 2 or a compound as claimed in claim 5 and 6 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

8. A composition which comprises a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 and an HMG CoA reductase inhibitor, ezetimibe, orlistat, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

9. A pharmaceutical composition as claimed in claim 7 or 8 in the form of a tablet, capsule, powder, syrup, solution or suspension.

10. A method for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

11. A method for treating and/or preventing a complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular

disorders; renal disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an antiinflammatory agent comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

12. A method of treating and/or preventing hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

13. A method for the treatment and/ or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

14. The method according to claim 13 wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.

15. A method for reducing total cholesterol, body weight, blood plasma glucose, insulin, HbA_{1C}, triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma comprising administering a compound of formula (I), as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

16. A method of treating and/or preventing hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according

to claim 7 or 8 in combination/concomittant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period so as to act synergistically and/ or additively.

17. A method according to claim 16, for treating and/or preventing a
5 complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal disease, glomerulonephritis,
10 glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an antiinflammatory agent
15 comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

18. A method for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist
20 of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 and a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period as to act synergistically and/or additively.

25 19. The method according to claim 18, wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.

20. A method of reducing plasma glucose, triglycerides, insulin, HbA_{1c}, total cholesterol, LDL, VLDL or free fatty acids or increasing HDL in the plasma, which
30 comprises administering a compound of formula (I) claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8, in combination/concomittant with a HMG CoA reductase inhibitor,

ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergistically and/or additively together to a patient in need thereof.

21. Use of a compound of formula (I) as defined in claim 1 or a compound as
5 claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance.

22. Use of a compound of formula (I) as defined in claim 1 or a compound as
10 claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 for treating and/or preventing a complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal
15 disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an
20 antiinflammatory agent.

23. Use of a compound of formula (I) as defined in claim 1 or a compound as
claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8
for treating and/or preventing hyperlipidemia, hypercholesteremia, hyperglycemia,
osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance,
25 insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism.

24. Use of a compound of formula (I) as defined in claim 1 or a compound as
claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8
for the treatment and/ or prophylaxis of disorders related to Syndrome X, which
30 comprises administering an agonist of PPAR α and/or PPAR γ .

25. Use of a compound according to claim 24 wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.

26. Use of a compound of formula (I) as defined in claim 1 or a compound as
5 claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 for reducing total cholesterol, body weight, blood plasma glucose, insulin, HbA_{1C}, triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma.

27. Use of a compound of formula (I) as defined in claim 1 or a compound as
10 claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 in combination/concomittant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period so as to act synergistically / additively for treating and/or preventing hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity,
15 impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism, to a patient in need thereof.

28. Use of a compound according to claim 27, for treating and/or preventing a complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia,
20 hypercholesteremia, hyperglycemia, osteoporosis, obesity, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic
25 ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an antiinflammatory agent comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to
30 claim 7 or 8 to a patient in need thereof.

29. Use of a compound of formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 in

combination/concomitant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period as to act synergistically / additively for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist of PPAR α and/or PPAR γ .

30. Use of a compound according to claim 29, wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.

31. Use of a compound of formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 in combination/concomitant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol for reducing plasma glucose, triglycerides, insulin, HbA_{1C}, total cholesterol, LDL, VLDL or free fatty acids or increasing HDL in the plasma.

32. A medicine for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

33. A medicine for treating and/or preventing a complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, atherosclerosis, leptin resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an antiinflammatory agent comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

34. A medicine for treating and/or preventing hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising
5 administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.
35. A medicine for the treatment and/ or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPAR α and/or PPAR γ of
10 formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.
36. The medicine according to claim 35, wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.
- 15 37. A medicine for reducing total cholesterol, body weight, blood plasma glucose, insulin, HbA_{1C}, triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma comprising administering a compound of formula (I), as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.
- 20 38. A medicine for treating and/or preventing hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as defined in claim 1
25 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 in combination/concomittant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period so as to act synergistically / additively.
- 30 39. A medicine according to claim 16, for treating and/or preventing a complication of diabetes said diabetes caused by insulin resistance or impaired glucose tolerance wherein the complication is dyslipidemia, stroke, hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, atherosclerosis, leptin


resistance, hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease and other cardiovascular disorders; renal disease, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis, or aldose reductase inhibitors or as an antiinflammatory agent comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 to a patient in need thereof.

40. A medicine for the treatment and / or prophylaxis of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8 in combination/concomittant with a HMG CoA reductase inhibitors, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol or their combination within such a period as to act synergistically / additively.

41. The medicine according to claim 40, wherein the disorder is hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or a cardiovascular disorder.


42. A medicine of reducing plasma glucose, triglycerides, insulin, HbA_{1C}, total cholesterol, LDL, VLDL or free fatty acids or increasing HDL in the plasma, which comprises administering a compound of formula (I) claimed in claim 1 or a compound as claimed in claim 5 or 6 or a pharmaceutical composition according to claim 7 or 8, in combination/concomittant with a HMG CoA reductase inhibitor, ezetimibe, orlistat, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergistically/additively together to a patient in need thereof.

43. Novel intermediate of formula (IIIh)




wherein n is an integer ranging from 0-4; W represents NR^7 , where R^7 represents hydrogen, linear or branched $(\text{C}_1\text{-C}_{12})$ alkyl, substituted or unsubstituted aryl, aralkyl group; Ar represents substituted or unsubstituted divalent single or fused aromatic or heterocyclic group; R^4 and R^5 may be same or different and represent hydrogen, hydroxy, alkoxy, halogen or substituted or unsubstituted groups selected from linear or branched $(\text{C}_1\text{-C}_{12})$ alkyl, aralkyl or heteroaralkyl groups; R^6 may be hydrogen or substituted or unsubstituted groups selected from $(\text{C}_1\text{-C}_{12})$ alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents oxygen or NR^8 , where R^8 represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; R^6 and R^8 together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, one or more nitrogen atoms and may optionally contain one or more heteroatoms selected from oxygen or sulfur; Q represents O, S, SO, SO_2 or NR^9 wherein R^9 represents hydrogen, substituted or unsubstituted groups selected from $(\text{C}_1\text{-C}_{12})$ alkyl, cycloalkyl, aryl, hydroxyalkyl, aralkyl heterocyclyl, heteroaryl, or heteroaralkyl groups; p is an integer of 0 or 1;

44. A process for the preparation of novel intermediate of formula (IIIi) defined in claim 43, which comprises, reacting a compound of formula (IIIi)



20 where all symbols are as defined in claim 43, with compound of formula (IIIj)



where L^1 is a leaving group and all other symbols are as defined in claim 43.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01104

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/36 A61K31/513 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 08501 A (REDDY RESEARCH FOUNDATION ;REDDY CHEMINOR INC (US)) 25 February 1999 (1999-02-25) page 1, line 5 -page 215; claim 1; example 47	1-44
X	EP 0 636 615 A (NISSAN CHEMICAL IND LTD) 1 February 1995 (1995-02-01) page 37, compound A-150 claim 1	1,2,4
X	PATENT ABSTRACTS OF JAPAN & JP 2000 159751 A (TORII YAKUHI), 13 June 2000 (2000-06-13) compound 38 abstract	1,3,4,7, 9,32-42
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 August 2002

Date of mailing of the international search report

09/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-2016

Authorized officer

Usuelli, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01104

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 334 598 A (HOECHST CELANESE CORP) 27 September 1989 (1989-09-27) page 4, formula (V); example 9 ---	43,44
X	US 3 804 839 A (BORCK J ET AL) 16 April 1974 (1974-04-16) column 4, formula (VII) ---	43,44
X	EP 0 712 844 A (GREEN CROSS CORP) 22 May 1996 (1996-05-22) examples 1,5,15 ---	43,44
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIU, C.; ET AL.: "Synthesis of some new pyrazolecarbonylureas and their biological activities" retrieved from STN, accession no. 1997:766522 Database accession no. 128:22856 XP002209181 RN:167843-89-2 abstract & HUAXUE YANJIU YU YINGYONG, vol. 9, no. 5, 1997, pages 497-499, ---	43,44
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MARCOS, M.; ET AL.: "Ferroelectric metallomesogenic palladium (II) complexes derived from bidentate Schiff bases" retrieved from STN, accession no. 1993:614333 Database accession no. 119:214333 XP002209184 RN: 150546-18-2 abstract & CHEM. MATER., vol. 5, no. 9, 1993, pages 1332-1337, ---	43,44
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/01104

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KULIEV, A; ET AL: "Synthesis of some alkyl esters of p-aminophenylmercaptoacetic acid" retrieved from STN, accession no. 1970:12299 Database accession no. 72:12299 XP002209185 abstract & AZERB. KHIM. ZH. , vol. 2, 1969, pages 74-76,	43,44
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; ARTICO, R.: Database accession no. 2728437 XP002209186 abstract & BIOCHEM. PHARMACOL., vol. 17, no. 6, - 1968 pages 893-894,	43,44
X	DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; BORDI, F; ET AL.: Database accession no. 6723252 XP002209187 abstract & FARMACO, vol. 44, no. 9, 1989, pages 795-808,	43,44
X	EP 0 587 311 A (SANKYO CO) 16 March 1994 (1994-03-16) Prparation 18 page 346, line 26	43,44
X	DE 36 34 862 A (FUJI PHOTO FILM CO LTD) 16 April 1987 (1987-04-16) example 2(2)	43,44
X	US 5 523 277 A (CONDON MICHAEL E ET AL) 4 June 1996 (1996-06-04) example 4	43,44
X	US 3 992 386 A (SCHACHT ERICH ET AL) 16 November 1976 (1976-11-16) example 12	43,44

-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/01104

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 248 554 A (ICI PLC) 9 December 1987 (1987-12-09) Formula (X), page 14 example 2, step (d) _____	43, 44

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/01104

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 10-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 43,44
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 43,44

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to the compounds of formula (IIIh) adequately supported by the description, namely the compounds in which:

R7 is H, CH₃ or C₂H₅

n and p are 0

Ar is 1,4-phenylene

Q is O, S

Y is O

R6 is H, alkyl

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/01104

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9908501	A	25-02-1999	AU 1120599 A CN 1280571 T EP 1073643 A2 US 2002103215 A1 WO 9908501 A2 US 6369067 B1	08-03-1999 17-01-2001 07-02-2001 01-08-2002 25-02-1999 09-04-2002
EP 0636615	A	01-02-1995	AU 666721 B2 AU 3905193 A EP 0636615 A1 US 5518994 A CN 1079736 A , B JP 6321913 A WO 9321162 A1	22-02-1996 18-11-1993 01-02-1995 21-05-1996 22-12-1993 22-11-1994 28-10-1993
JP 2000159751	A	13-06-2000	NONE	
EP 0334598	A	27-09-1989	US 4883901 A CA 1331013 A1 EP 0334598 A2 JP 2004744 A US 5235090 A	28-11-1989 26-07-1994 27-09-1989 09-01-1990 10-08-1993
US 3804839	A	16-04-1974	DE 2112272 A1 AT 327900 B AT 214872 A BE 780604 A1 CA 955597 A1 CH 574449 A5 CH 576986 A5 CS 163791 B2 ES 400742 A1 FR 2130175 A5 GB 1327164 A HU 164469 B IL 38723 A NL 7201169 A SE 382809 B US 3856812 A US 3925394 A ZA 7200611 A	05-10-1972 25-02-1976 15-05-1975 13-09-1972 01-10-1974 15-04-1976 30-06-1976 07-11-1975 01-07-1975 03-11-1972 15-08-1973 28-02-1974 22-10-1974 19-09-1972 16-02-1976 24-12-1974 09-12-1975 25-10-1972
EP 0712844	A	22-05-1996	JP 8231548 A CA 2168858 A1 CN 1131418 A EP 0712844 A1 WO 9533720 A1 JP 2990042 B2 JP 8053398 A TW 415940 B US 5635527 A US 5753670 A	10-09-1996 14-12-1995 18-09-1996 22-05-1996 14-12-1995 13-12-1999 27-02-1996 21-12-2000 03-06-1997 19-05-1998
EP 0587311	A	16-03-1994	AU 4443893 A CA 2103536 A1 CN 1091432 A CZ 9301619 A3 EP 0587311 A1	10-02-1994 08-02-1994 31-08-1994 16-02-1994 16-03-1994

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/IB 02/01104

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0587311	A		FI 933472 A	08-02-1994
			HU 64774 A2	28-02-1994
			IL 106600 A	30-09-1997
			JP 6100533 A	12-04-1994
			KR 177838 B1	01-04-1999
			MX 9304837 A1	31-05-1994
			NO 932813 A	08-02-1994
			NZ 248332 A	27-01-1995
			RU 2106357 C1	10-03-1998
			US 5629406 A	13-05-1997
			ZA 9305697 A	10-03-1994
DE 3634862	A	16-04-1987	JP 1822006 C	10-02-1994
			JP 5033676 B	20-05-1993
			JP 62090285 A	24-04-1987
			DE 3634862 A1	16-04-1987
			GB 2181564 A , B	23-04-1987
US 5523277	A	04-06-1996	US 5496954 A	05-03-1996
			US 5545742 A	13-08-1996
			ZA 9600901 A	05-08-1997
US 3992386	A	16-11-1976	DE 2312344 A1	19-09-1974
			DE 2319642 A1	14-11-1974
			DE 2325184 A1	05-12-1974
			AT 340420 B	12-12-1977
			AT 204474 A	15-04-1977
			AU 6654774 A	18-09-1975
			BE 812121 A1	11-09-1974
			CS 179439 B2	31-10-1977
			DD 110494 A5	20-12-1974
			ES 424179 A1	16-01-1977
			ES 446532 A1	16-10-1977
			FR 2221135 A1	11-10-1974
			GB 1422926 A	28-01-1976
			HU 168080 B	28-02-1976
			IL 44356 A	31-10-1977
			JP 49125358 A	30-11-1974
			NL 7403309 A	17-09-1974
			SE 7605082 A	04-05-1976
			US 4053626 A	11-10-1977
			ZA 7401400 A	26-02-1975
			CS 179446 B2	31-10-1977
			CS 179447 B2	31-10-1977
EP 0248554	A	09-12-1987	AT 85329 T	15-02-1993
			AU 595317 B2	29-03-1990
			AU 7332487 A	03-12-1987
			BR 8702763 A	01-03-1988
			CN 87104533 A , B	20-01-1988
			DE 3783951 D1	18-03-1993
			DE 3783951 T2	03-06-1993
			EP 0248554 A2	09-12-1987
			ES 2053536 T3	01-08-1994
			GR 3006964 T3	30-06-1993
			JP 62286975 A	12-12-1987
			KR 9006838 B1	22-09-1990
			PH 23199 A	06-06-1989

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/01104

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0248554	A	PH 23330 A	14-07-1989

